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                     The present work aims to investigate the anti-diabetic effects of Averrhoa bilimbi 
leaves in animals with experimental diabetes mellitus.  The ethanolic leaf extract 
of A.bilimbi (ABe) was evaluated for its antidiabetic activity in streptozotocin 
(STZ) induced diabetic Sprague-Dawley (SD) rats. At a dose of 125 mg/kg body 
weight, ABe increased glucose tolerance in an oral glucose tolerance test (OGTT) 
in these rats. Moreover, it showed potent hypoglycemic, hypotriglyceridemic, anti-
lipid peroxidative and anti-atherogenic activities when administered twice a day 
for 2 weeks.   
 
                     ABe was partitioned with organic solvents - butanol, ethyl acetate and hexane - to 
obtain aqueous (AF), butanol (BuF), ethyl acetate (EF) and hexane (HF) soluble 
fractions. The hypoglycemic property of each fraction was assessed by OGTT at a 
dose of 125-mg/kg-body weight in both STZ and high fat diet fed (HFD)-STZ 
diabetic rats. AF and BuF produced significant improvement in glucose tolerance. 
In the long-term study, twice a day administration of AF and BuF also at a dose of 
125 mg/kg for 14 days in both STZ/HFD-STZ diabetic rats showed a significant 
blood glucose lowering action.   
 
                     
 
 xxii
                     
                    
                    Moreover, AF was found to be more potent than BuF and increased serum insulin 
level in STZ-diabetic rats as well as lowered hepatic glucose-6-phosphatase 
activity significantly in both STZ/HFD-STZ diabetic rats and these results 
indicated that AF is more potent than BuF in the amelioration of hyperglycemia in 
both STZ and HFD-STZ-diabetic rats.   AF was more potent in the amelioration of 
diabetes and β-cell protection against streptozotocin toxicity than BuF.  
                      
                     Reverse-phase high performance liquid chromatography (RP-HPLC) of AF and 
BuF revealed the presence of nicotinic acid (NA) in these fractions. In addition, the 
atomic absorption spectrophotometric analysis (AAS) showed the presence of 
magnesium (Mg) in higher concentration in AF than BuF.  Hence, the effects of 
both Mg and NA on glucose tolerance were tested in four different animal models 
of diabetes viz., STZ-diabetic SD rats and STZ-diabetic C57BL/6J; both represent 
the type 1 diabetic model while HFD-STZ-diabetic SD rats and HFD-fed 
C57BL/6J represent type 2 diabetic model. The administration of both NA and Mg 
together improved glucose tolerance more than either Mg or NA alone. This 
synergistic interaction of NA and Mg in A.bilimbi extract could be one of the 















         1. Diabetes mellitus and blood glucose homeostasis 
            1.1 Diabetes mellitus and its diagnosis 
Diabetes mellitus is a principal cause of morbidity and mortality in human 
populations (Steppan et al., 2001). It is a syndrome characterized by 
hyperglycemia, polydipsia and polyuria and causes complications to the eyes, 
kidneys, and nerves. It is also associated with an increased incidence of 
cardiovascular disease (Pickup and Williams, 1991). The clinical manifestations 
and development of diabetes often differ significantly between countries and also 
between racial groups within a country. For example, diabetes currently affects an 
estimated 15.1 million people in North America, 18.5 million in Europe, 51.4 
million in Asia, and just under 1 million in Oceania (Kuhlmann, 1996). It is 
estimated that globally, the number of people will rise from 151 million in the year 
2000 (Amos et al., 1997), to 221 million by the year 2010, and to 300 million by 
2025 (King et al., 1998).  
 
Diabetes mellitus is becoming increasingly common in Singapore population. The 
prevalence of type 2 diabetes doubled between 1984 and 1992 in Singaporean 
Chinese (Chen et al., 1999).  This increase can be attributed to many factors, 
including a stressful lifestyle as well as improper dietary habits.  This is of 
economic concern as the disease requires life-long treatment and is also associated 





The clinical diagnosis of diabetes is often suggested by the presence of 
hyperglycemic symptoms and glycosuria, sometimes with drowsiness or coma. 
The World Health Organization (WHO) criteria define diabetes by fasting plasma 
glucose (FPG) level of 140mg/dL (7 mmol/L) or greater, or post-prandial 2-h 
plasma glucose (PG) level of 200mg/dL (11.1 mmol/L) or greater during an oral 
glucose tolerance test (WHO, 1985). 
 
The National Diabetes Data Group of the National Institutes of Health 
recommends the following criteria for diagnosing diabetes: 
a. Fasting (overnight) venous plasma glucose concentration greater than or 
equal to 140 mg/dL on at least two separate occasions. 
b. Venous plasma glucose concentration greater than or equal to 200 mg/dL at 
2-h post-ingestion of 75 g of glucose and at least one other sample during 
the 2-h test. 
 
1.2 The classification of diabetes mellitus 
Diabetes mellitus represents a heterogeneous group of disorders. Some distinct 
diabetic phenotypes can be characterized in terms of specific aetiology and/or 
pathogenesis, but in many cases overlapping phenotypes make etiological and 
pathogenetic classification difficult (Leslie, 1997). In general, diabetes mellitus  
can be classified into two major types: insulin-dependent diabetes mellitus (IDDM, 
Type 1 diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, Type 2 
diabetes), based principally upon clinical symptoms and, when possible, on more 
specific etiologic characterization. In IDDM, there is destruction of the β-cells of 
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the pancreas, with consequent insulin deficiency. At clinical presentation, IDDM is 
often associated with marked hyperglycemia and its attendant symptoms and signs: 
polyuria, polydipsia, and unexplained weight loss. The cause of NIDDM is often a 
combination of resistance to insulin action and inadequate compensatory insulin 
secretion. Although patients with this type of diabetes may have insulin levels that 
appear normal, insulin levels always are low relative to the elevated plasma 
glucose levels (Ward et al., 1984). In NIDDM, hyperglycemia sufficient to cause 
functional and pathologic changes in target organs may be present without clinical 
symptoms. The incidence of each type of diabetes varies widely throughout the 
world. There are genetic and environmental components in the causation of both 
IDDM and NIDDM (Zimmet et al., 1989). 
 
1.3 Incidence and epidemiology 
The incidence of diabetes mellitus in the United States is estimated at 
approximately 4.5%, of which 85-90% are NIDDM and the rest IDDM. In 1992, 
while diabetics accounted for only 4.5% of the US population, their care required 
roughly 14.6% of the total US health care expenditures ($105 billion). Annually, 
between 500,000 and 600, 000 Americans are detected with NIDDM. More than 
75% of the individuals with diabetes will develop neurological, microvascular, or 
macrovascular complications (Mazze, 1994). 
 
The prevalence of diabetes mellitus is rising and it is now the seventh leading 
cause of death in USA. At the current rate of increase (6%/year), the numbers of 
diabetics will double every 15 years. Epidemiologically, diabetes mellitus has been 
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linked to the western lifestyle and is uncommon in cultures consuming a more 
“primitive” diet. As cultures switch from their native diets to the “foods of 
commerce”, their rate of diabetes mellitus increases, eventually reaching the same 
proportions seen in Western societies.  
 
1.4 Regulation of glucose metabolism by insulin and pathophysiology of 
diabetes 
Plasma glucose concentrations are effectively maintained within a fairly narrow 
range despite wide fluctuations in the body’s supply (e.g. meals) and demand (e.g. 
exercise) for nutrients (Gerich, 1993). Changes in plasma blood glucose levels are 
moderated by the actions of the liver primarily under the control of insulin and 
glucagon (Unger and Orci, 1981). Insulin, secreted by the β-cells of the pancreas, 
lowers the concentration of glucose in blood by inhibiting hepatic glucose 
production and stimulating the uptake and metabolism of glucose by muscle and 
adipose tissue (Davis and Granner, 1996). 
 
All forms of diabetes mellitus are due to a decrease in the circulating concentration 
of insulin (insulin deficiency) and a decrease in the response of peripheral tissue to 
insulin (insulin resistance). These abnormalities lead to alterations in the 
metabolism of carbohydrates, lipids, ketones, amino acids; the central feature of 
the syndrome is hyperglycemia. Insulin plays a role in regulating both 
glycogenolysis and gluconeogenesis in liver (Cherrington et al., 1987). The 
absence or deficiency of insulin’s effects not only engenders an increased hepatic 
net extraction of glucogenic amino acids, lactate, glycerol and their conversion to 
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glucose, but also stimulates both the quantity and activity of gluconeogenesis 
enzymes, such as glucose-6-phosphatase (Glc-6-Pase), fructose-1,6-bisphosphatase 
and pyruvate carboxylase (Weber, 1964; Taunton et al., 1974). The enzyme, Glc-
6-Pase, catalyzes the terminal step in both gluconeogenic and glycogenolytic 
pathways, so it is a key determinant in the production of glucose by the liver. Both 
mRNA levels and activity of Glc-6-Pase are low in the fed and refed states, where 
insulin levels are elevated. Both mRNA levels and activity of Glc-6-Pase are 
elevated in diabetic rats and administration of insulin to diabetic rats results in the 
reduction of the mRNA and activity of this enzyme (Argaud et al., 1996; Massillon 
et al., 1996). 
 
Insulin has many actions within the central nervous system (CNS), including 
reducing food intake and body weight and interacting in predictable ways with 
other controllers of meal size (McGowan et al., 1990). On the other hand, its 
anabolic effects in peripheral tissue would promote weight gain. These two major 
actions of insulin tend to counterbalance one another, as the peripheral anabolic 
effect of insulin would cause weight gain yet appetite would be suppressed via 
insulin’s central catabolic action (Schwartz et al., 1994). It is believed that insulin 
and leptin (Zhang et al., 1994), an adipose tissue hormone, modulate energy 
homeostasis, such as causing change in food intake and body weight at the brain 






Hypoinsulinemia and low circulating leptin concentrations may contribute to 
hyperphagia via upregulation of hypothalamic neuropeptide Y (NPY) system in 
uncontrolled type I diabetes (Havel et al., 1998). However in this kind of diabetes, 
the extreme hypoinsulinemia causes a wasting of peripheral tissue and consequent 
weight loss due to the lack of a peripheral insulin anabolic effect, even though 
there is also a concomitant enhanced appetite in this situation (The DCCT study 
group, 1988).  
 
Insulin stimulates lipoprotein lipase activity and promotes fat and muscle storage 
of both exogenously derived triglycerides as well as that produced endogenously 
(Eckel and Yost, 1987). It also inhibits the hormone-sensitive lipase in adipose 
tissue and thus inhibits the hydrolysis of triglycerides stored in the adipocytes. 
Elevations in plasma triglycerides and cholesterol are evident in diabetic animals. 
This is related to decreases in activity of insulin-dependent lipoprotein lipase and 
in the apoprotein content of lipoproteins (Tavangar et al., 1992; Sparks et al., 
1992), necessary for the recognition and efficient lipolysis of the triglyceride-rich 
particles at the sites of their uptake.  
 
Steady-state levels for insulin mRNA appears to be important for regulation of 
insulin production. Insulin mRNA levels varied with the change in demand for 
insulin in several experimental conditions and correlated directly with rates of 
insulin biosynthesis when both were measured in vivo (Permutt et al., 1984; 




In a rat model for diabetes, maintenance of glucose homeostasis correlated with 
maintenance of pancreatic insulin mRNA content. When prediabetic or mildly 
glucose intolerant rats were challenged with a diabetogenic agent, maintenance of 
normal glucose levels correlated with increases in insulin mRNA content. When 
this adaptive response failed, hyperglycemia worsened (Giddings et al., 1985). 
After administration of STZ and alloxan, a marked reduction in insulin mRNA 
level was observed (Mulder et al., 1995). 
 
The insulin gene is present as a single copy in most species. However, in rats, two 
nonallelic insulin genes (Insulin I gene and Insulin II gene) are expressed (Clark 
and Steiner, 1969; Lomedico et al., 1979). Their mRNAs are quite similar, being 
approximately 93% homologous in the coding regions with only 34 of 439 
nucleotides different (Ullrich et al., 1977). Insulin I gene has been observed to be 
expressed in pancreas, but insulin II, the ancestral gene, is expressed not only by 
pancreas but also by extra pancreatic tissue, including yolk sac and fetal liver 
(Giddings and Carnaghi, 1989). The two rat insulin genes may function 
independently. The conversion products, insulin I and II, are usually stored in 
unequal amounts. The ratio of the cellular contents of insulin I over insulin II 
fluctuates between 1 and 2 in a basal fed or fasting state, but increases 2- to 4-fold 
during pregnancy or chronic hyperglycemia. Glucose is an important modulator of 
the rate of insulin biosynthesis, through changes in mRNA levels. (Kakita et al., 
1982). Rat β-cells exhibit a differential regulation of biosynthesis of the two 
insulin isoforms at the level of both transcription and translation. This leads to an 
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increase in the ratio of insulin I over insulin II in terms of both their respective 
mRNA content as well as their peptide content (Ling et al., 1998).  
 
            1.5 Free radicals and the complications of diabetes 
The causes of death in the diabetic population changed drastically after the advent 
of insulin therapy by Banting and Best in 1922. While insulin and other medical 
treatments can control many aspects of diabetes, numerous complications are not 
uncommon. The microvascular, neuropathic and macrovascular complications are 
a major health problem for patients with either IDDM or NIDDM (Herman and 
Crofford, 1998). Oxidative damage appears to be involved in the pathogenesis of 
long-term complications in diabetes, based on the increased concentration of lipid  
peroxidation products and the accumulation of advanced glycosylation end 
products and glycoxidation products in tissue proteins of diabetic patients with 
complications. Enzymatic and non-enzymatic oxidation of lipids and 
carbohydrates yield reactive carbonyl compounds, including aldehydes derived 
from lipid peroxidation and dicarbonyl sugars derived from glucose, which are key 
intermediates in the chemical modification and cross-linking of proteins in 
diabetes (Baynes, 1995).  
 
Oxygen free radicals (OFRs), such as superoxide (O2•−), hydrogen peroxides 
(H2O2) and hydroxyl radicals (OH•), are implicated in the pathophysiology of 
ischemia/reperfusion injury and atherosclerosis (McCord, 1985; Mantha et al., 
1993). Oxidation of lipids in plasma lipoproteins and in cellular membranes is 
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associated with the development of vascular disease in diabetes (Morel et al., 
1983). Much of the experimental evidence suggests that diabetes and 
hyperlipidemia alone are not sufficient to provoke vascular disease but oxidative 
stress may be an important and independent risk factor in the development of 
vascular disease (Hunt et al., 1990). Although antioxidant therapy has not been 
adequately tested, it may provide an important defense against oxidative damage 
and the development of complications in diabetes.  
 
1.6 Animal models of diabetes and prevention of diabetes 
1.6.1 Chemically-induced diabetes in animals 
Chemically induced type I diabetes is the most commonly used animal model of 
diabetes. Alloxan (2, 4, 5, 6-tetraoxo hexahydro pyrimidine) was the first agent 
that was reported to produce permanent diabetes in laboratory animals (Dunn, 
1943). Streptozotocin (STZ) has replaced alloxan as the principal agent used to 
produce experimental diabetes. This is due to the greater selectivity of β-cells for 
STZ (Junod et al., 1969) and lower mortality rate seen in STZ-diabetic animals 
(effective diabetogenic dose of STZ is four or five times less than its lethal dose) 




























Figure 1.  Molecular structure of streptozotocin (STZ). 
 
 
The chemical structure of STZ (Figure 1) comprises a glucose molecule with a 
highly reactive nitrosourea side chain that is thought to initiate its cytotoxic action.  
As previously reported, diabetes was consistently produced at doses of 50-70 
mg/kg of STZ (Ar’Rajab and Ahren, 1993). The absence of ketosis in animals 
having received intravenous STZ at doses of 65 mg/kg or less is adequately 







































As shown in Figure 2, the glucose moiety directs this agent to the pancreatic β-
cells, where it binds to a membrane receptor to cause structural damage (Johansson 
and Tjalve, 1978). The deleterious effect of STZ results from the generation of 
highly reactive carbonium ions (CH3+) that cause DNA breaks by alkylating DNA 
bases at various positions, resulting in activation of the nuclear enzyme, 
poly(ADP-ribose) synthetase, thereby depleting the cellular enzyme substrate 
(NAD+), leading to cessation of NAD+-dependent energy and protein metabolism. 
This in turn leads to reduced insulin secretion (Yamamoto et al., 1981). It has been 
suggested that free radical stress occurred during β-cell destruction mediated by 
mononuclear phagocytes and cytokines (Pitkanen et al., 1992; Nagy et al., 1989). 
Since free radical scavengers have been demonstrated to protect against the 
diabetogenic properties of STZ (Robbins et al., 1980), it is likely that oxidative 
stress may play a role in determining STZ toxicity. 
 
Some poly (ADP-ribose) synthetase inhibitors, such as nicotinamide and 3-
aminobenzamide, could prevent the onset of diabetes (Uchigata et al., 1983).  It 
was also reported that metallothionein, a free radical scavenger, could provide 
some protection against the diabetogenic properties of STZ (Yang and Cherian, 
1994). Cytoprotective components, such as zinc (Yang and Cherian, 1994) and 
lipid components from the soybean (Lee and Park, 2000) may prevent β-cell death 
by stabilizing membrane integrity and normalizing membrane biochemical 
alterations.  
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           1.6.2 Diabesity-prone C57BL/6J mice  
The non-obese, non-diabetic BL/6J mice, the genomic host of the ob/ob mutation, 
are susceptible to diabesity when placed on an affluent fat and sucrose-rich diet. 
They become hypertensive and exhibit an insulin-resistant syndrome: increased 
outflow from the sympathetic nervous system, deranged β-cell function and 
adipocyte metabolism, hyperleptinemia but without hyperphagia or elevation of 
corticosterone secretion (Martin-Dixton et al., 2002).  
 
Genetic mapping has identified differences in the expression of uncoupling protein 
(UCP2) which may have a role in the development of diabesity (Petro and Surwit, 
2000). Thus, inbred laboratory mice, without overt metabolic disturbance, were 
demonstrated to be vulnerable to metabolic abnormalities on high fat diet (HFD). 
The hyperinsulinemia most probably interferes with the action of catecholamines 
on β1 and β3 adrenergic receptors, thereby affecting the uptake of glucose by 
adipocytes and increasing the sympathetic outflow. Thus, the C57BL/6J mice 
present an attractive model for the study of multiple endocrine abnormalities 
induced by dietary hyperinsulinemia (Shafrir, 2003). 
 
           1.7 Oral hypoglycemic agents 
Oral hypoglycemic agents that could effectively control the abnormalities of 
carbohydrate, lipid, and protein metabolism that occur in patients with diabetes 
have been used for over half a century. There are two major structurally and 
functionally different oral antidiabetic drug classes, the sulfonylureas and the 
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biguanides, that are widely used in the world. The sulfonylureas include 
chlorpropamide, glibenclamide and tolbutamide. Both pancreatic and extra-
pancreatic effects have been suggested to contribute to the therapeutic benefit of 
sulfonylureas for type II diabetic patients. Sulfonylureas directly stimulate insulin 
release from the β-cells in the islets of Langerhans, and this effect do not require 
the presence of glucose or other secretagogues (Gorus et al., 1988).  
 
Among biguanides, metformin and phenformin have been employed for oral 
diabetic therapy since 1960s (Bailey, 1992). Only metformin was approved for use 
in the United State in early 1995. Phenformin was withdrawn in many countries 
during 1970s because of its association with lactic acidosis.   In contrast to 
sulfonylureas, metformin has blood glucose reducing effect only in diabetes; and it 
does not produce hypoglycemia in normal subjects. Metformin also exerts little or 
no effect on basal insulin release by the pancreas or isolated islets of nondiabetic 
animals (Schatz et al., 1972; Gregorio et al., 1989). 
 
Alpha-glucosidase inhibitors, such as Acarbose, found in the mid-1990, has 
rationalized and simplified the treatment of diabetes. It is a competitive inhibitor of 
the major α-glucosidase enzymes in the brush border of the mucosal cell of the 
small intestine. It inhibits the digestion of the complex carbohydrates in the upper 
jejunum so that they are digested throughout the length of the small intestine. The 




Thiazolidinedione (TZDs) analogues (Glitazones or TZDs), a new class of 
antidiabetic drugs represented by ciglitazone, have been shown to be effective 
antihyperglycemic compounds in animal models of non-insulin dependent diabetes 
mellitus (NIDDM) (Fujita et al., 1983). The two analogues in this chemical series, 
pioglitazone (Sugiyama et al 1990b) and rosiglitazone (Fujiwara et al, 1988) are 
now available for therapeutic use (Lebovitz, 1997). 
 
1.8 Botanical medicines 
Before the advent of insulin, diabetes was treated with plant medicines. The World 
Health Organization (WHO) urged researchers to examine whether traditional 
medicines produced any beneficial clinical results (WHO, 1980).  The plant 
kingdom represents a largely unexplored reservoir of biologically active 
compounds not only as drugs, but also as unique templates that could serve as a 
starting point for synthetic analogs and an interesting tool that can be applied for a 
better understanding of biological processes. Folkloric uses are supported by a 
long history of human experience. Numerous biologically active plants are 
discovered by evaluation of ethnopharmacological data, and these plants may offer 
the local population immediately accessible therapeutic products (Aquino et al., 
1995).  
 
The earliest known documentation of plant-derived treatments for diabetes is 
found in the Ebers Papyrus of about 1550 BC. Since then, multitudes of herbs, 
spices, and other plant materials have been described for the treatment of diabetes 
throughout the world (Bailey and Day, 1989). Traditional anti-diabetic plants 
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might provide a useful source of new oral hypoglycemic compounds for 
development as pharmaceutical entities, or as simple dietary adjuncts to existing 
therapies. However, since the availability of insulin, folklore medicines for 
diabetes have almost disappeared from occidental societies, although they continue 
to be the cornerstone of therapy in underdeveloped regions.  
 
Renewed attention to alternative medicines and natural therapies has stimulated a 
new wave of research interest in traditional practices. In the last 20 years, scientific 
investigation has confirmed the efficacy of many of these preparations, some of 
which are remarkably effective. Mentioned hereafter are those plants that appear 
most effective, are least toxic, and have substantial documentation of efficacy. 
 
More than 400 different plants and plant extracts have been described for the 
diabetic patient. From these, various molecular species with hypoglycemic activity 
have been identified, including alkaloids, flavonoids, glycosides, and 
polysaccharides (Day, 1990).  For example, castanospermine, an alkaloid isolated 
from seeds of Castanospermum australe; epicatechin, a flavonoid isolated from the 
heartwood of Pterocarpus marsupium; and neomyrtillin, a glycoside isolated from 
Vaccinium myrtillus, were claimed to exert hypoglycaemic effect (Day, 1990). 
Like the sulfonylureas, some plants act by increasing the release of insulin and 
require a minimum of β-cells to exert their action. These plants include 
Momordica foetida (Marquis et al., 1977), Euphorbia prostrata and Fumaria 
parviflora (Akhtar et al., 1984), Taraxacum officinale (Akhtar and Ali, 1985) and 
Eribotry japonica (Noreen et al., 1987). Like metformin, other plant extracts, such 
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as Aloe (Al-Awadi et al., 1985), Momordica charantia (Sarkar et al., 1996), 
Cecropia obtusifolia, Coccinia indica and Hammada salicornia (Ivorra et al., 
1989) act by modifying glucose metabolism rather than altering insulin levels. 
Some are shown to correct complications of diabetes, for example, masoprocol, a 
pure compound isolated from Larrea tridentata, which decreases the elevated 
levels of serum cholesterol, free fatty acids and triglycerides in fat-fed/diabetic rats 
(Reed et al., 1999). Even with the use of these herbs, which possess blood glucose 
lowering effects, proper and effective natural treatment of diabetics require careful 













1.9 Averrhoa bilimbi Linn. 
Averrhoa bilimbi Linn (Oxalidaceae) (Figure 3) is a small-sized tree growing up to 
15 m tall and 30 cm in diameter. Young parts are covered with long persistent, 
yellowish to rusty, velvety hairs. Leaves are compound, often crowded at the ends 
of the branches with 7-19 leaflets each measuring up to 12 cm by 4 cm, variable in 
shape with 6-14 pairs of lateral veins. Flowers are borne in dense, fascicled, 
pendulous clusters on bare branches and on knobby protuberances along the tree 
trunk; calyx is yellowish green, and petals red to purple. Fruits are rounded and 
angular in cross section, up to 10 cm by 5 cm, fleshy and juicy but acidic when 
ripe.  Though widely cultivated in the low lands of Southeast Asia, its country of 
origin is unknown but tropical America has been suggested. The plant flowers and 
fruits intermittently throughout the year.  The other names are viz., Averrhoa 
obtusangula Stokes; Belimbing asam, Belimbing buluh, Belimbing wuluh (Malay, 
Javanese); Kamias, kalamias, Iba, Kolonanas (Tag); Ta-ling-pring (Thai). 
            
           1.9.1 Chemical constituents of A.bilimbi 
The chemical compounds that have been identified in A.bilimbi include amino 
acids, citric acid, cyanidin-3-O-β-D-glucoside, phenolics, potassium ion, sugars 
and vitamin A. 
 
1.9.2 Ethnopharmacological uses of A.bilimbi 
The fruits of A.bilimbi possess antibacterial, antiscorbutic, astringent and post-
partum protective properties. The decoction of the leaves is being used as medicine 
for treating fever, inflammation of the rectum, diabetes, mumps and pimples. The 
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paste of leaves is being used for the treatment of itches, boils, rheumatism, cough 
and syphilis. The juice of preserved fruits is being used for the treatment of scurvy, 
stomach ache, bilious colic, whooping cough, and hypertension. Moreover, the 























1.10 Aims of the thesis 
A preliminary study in our laboratory showed decreases in blood glucose levels 
and food intake in STZ-diabetic rats given aqueous or ethanolic extracts of A. 
bilimbi fruits and leaves intraperitoneally (Tan et al., 1996). However no reports 
are available about the constituent(s) of A. bilimbi which is responsible for the 
anti-diabetic activity and the mechanism (s) of its anti-diabetic action.  Hence the 
aims of this thesis are to: 
a) investigate the effects of ethanol-extract of A.bilimbi (ABe) leaves on blood 
glucose and lipid levels in STZ- diabetic rats 
b) identify the bioactive semi-purified fraction(s) of ABe by bioassay guided 
fractionation  
c) evaluate the β-cell protective effect of ABe and its bioactive fractions 
against STZ in rats 
d) investigate the anti-diabetic effects of the bioactive fractions of A.bilimbi in 
rat model of type 2 diabetes 
e) isolate and characterize  the anti-diabetic principle (s) of A.bilimbi  
f) evaluate the effect of the anti-diabetic principle (s) of A.bilimbi on glucose 
tolerance in animals with type 1 and type 2 experimental diabetes mellitus 
 
It is expected that this study could provide a scientific basis for the use of this plant 









MATERIALS AND METHODS 
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Section 1.  Materials 
            1.1 Chemicals and reagents 
BDH Laboratory Supplies (England) 
Sodium citrate 
            Bio-Rad Laboratories (Hercules, CA, USA) 
Bio-Rad protein assay reagent 
Merck KGaA (Darmstadt, Germany) 
Acetone; Methanol; nButanol; Ethanol; Hexane; Chloroform; HCl; H2SO4; 
Dodecyl sulphate sodium (SDS); Isopropyl alcohol; Potassium dihydrogen 
phosphate (KH2PO4); Phosphoric acid; Potassium chloride; Sucrose; 
Trichloroacetic acid (TCA) 
            Sigma-Aldrich (St Louis, MO, USA) 
All other chemicals and reagents used in the present study 
 
            1.2 Kits 
Sigma Diagnostics, INC. (St Louis, MO, USA) 
Glucose assay kit (Trinder method) 
Boehringer Mannheim (GmbH, Mannheim, Germany) 
Cholesterol (TG) reagent; Peridochrom® Triglyceride (TC) reagent 





R&D systems (MN, USA) 
Rat leptin ELISA kit 
Mercodia (Uppsala, Sweden) 
Rat insulin ELISA kit 
I-STAT portable glucose analyzer (i-STAT Corporation, East Windsor, NJ, USA) 
 
1.3 Facilities 
Buchi rotary evaporator R-144 (Buchi Labortechnik AG, Switzerland) 
Buchi water bath B-480 (Buchi Labortechnik AG, Switzerland) 
Chemical hood (Pacific Vinitex Pte Ltd, Singapore) 
-86°C Freezer (Forma Scientific) 
-20°C & 4°C ACMA Refrigerator 
Balance (Precisa 40SM-200A, Swiss) 
Beckman Avanti™ J-25I Centrifuge (Fullerton, CA, USA) 
Beckman JA 25-25 Rotor (Fullerton, CA, USA) 
Beckman Optima™ L-90K Ultracentrifuge (Fullerton, CA, USA) 
Beckman Type 70 Ti Rotor (Fullerton, CA, USA) 
ELX 800 Microplate Reader (Bio-Tek Instruments Inc., USA) 
Jouan Centrifuge (Everbloom Medical & Scientific Pte. Ltd., Singapore) 
Kubota KR-20000T Centrifuge (Kubota Seisakusho Co., Ltd., Japan) 
Kubota RA-1M Micro Tube × 16 Rotor (Kubota Seisakusho Co., Ltd., Japan) 
Perkin-Elmer 1100B Atomic Absorption Spectrophotometer 
            Polytron Homogenizer (Polytron, Switzerland) 
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Table 1.  Composition of the basic rodent diet, AIN-93G 
         
         ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 
                    Ingredient                                                                  Content (g/kg food) 
         ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 
                    Casein                                                                              178.6                              
                    Sucrose                                                                            100 
                    Starch                                                                               367.5 
                    Dextrinished starch                                                          132 
                    Methionine                                               3 
                    Choline chloride (50%, w/w)                    2.5 
                    Natural oil                                   100 
                    AIN-93M minerals                                                           10 
                    AIN-93M vitamins                                                           35 
 
                    Total           1000 













            SYNERGI 4 u hydro- RP 80A (Part No: 00G-4375-E0) column (Phenomenex) 
Shimadzu Class LC-10 (version 1.64) with PC control 
UV-1601 Spectrophotometer (Shimadzu, Japan) 
Waring blender (Waring Laboratory, Torrington, CT, USA) 
Water Incubator (Everbloom Medical & Scientific Pte, Ltd., Singapore) 
            
            1.4 Animals 
Male Sprague-Dawley (SD) rats, aged 10 weeks (220-260 g), were obtained from 
The Laboratory Animal Center, National University of Singapore. The rats were 
housed in individual cages in an animal room with lighting from 0600 to 1800 h 
and maintained on standard pelleted diet, AIN-93G, (Table 1) (Glen Forrest, WA, 
Australia) with water ad libitum. 
Male C57BL/6J (Animal Holding Unit, National University of Singapore, 
Singapore), 6 weeks of age, were used for all studies.  They were housed about 6 
per cage in a room with a 12-h light and 12-h dark and an ambient temperature of 
22-25º C.   
 
2. Methods 
            2.1 Preparation and partitioning of plant extract 
2.1.1 Preparation  
The plant was collected from a private garden and identified as Averrhoa bilimbi 
by Dr. Ruth Kiew, Keeper of Herbarium and Library, Singapore Botanic Gardens.  
A dried specimen was deposited in the herbarium (Voucher specimen No. BT 2).  




 Figure 4. Schematic representation of the bio-assay guided fractionation procedure for  
 the isolation of anti-diabetic principle (s) from A.bilimbi leaves. 
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 (10 L) until exhaustion.  The mixture was filtered with Whatman No 1 filter paper 
(Whatman International Ltd., England).  The filtrate was centrifuged for 10 
minutes at 10,000g to remove particulate substances.  The clear supernatant was 
concentrated at 40°C, using a rotavapor (Buchi Labortechnik AG, Switzerland) to 
1 L. The concentrate was freeze-dried and suspended in distilled water before use.  
 
2.1.2 Partitioning  
The clear supernatant of 80% ethanolic extract (prepared according to Method 
2.1.1) was partitioned between butanol and water to obtain the aqueous fraction 
(AF) and the butanol fraction (BuF). The AF was further partitioned by ethyl 
acetate and hexane to obtain the ethyl acetate (EF) and hexane soluble fractions 
(HF). Each fraction was concentrated at 40°C, using a rotavapor (Buchi 
Labortechnik AG, Switzerland) and freeze-dried, to yield about 40 g of AF, 25g of 
BuF, 15 g of EF and 12 g of HF. The extract was suspended in distilled water 
before use. 
 
2.2 Streptozotocin (STZ)-induced diabetic rats 
After fasting for 18-h, the rats were intraperitoneally injected with a single dose of 
60 mg/kg STZ, freshly dissolved in citrate buffer (0.01 M, pH 4.5). Diabetes in the 
rats was identified by polydipsia, polyuria and by measuring non-fasting serum 
glucose concentration 48-h after injection of STZ. Rats with a serum glucose level 







   Table 2.  Composition of the high fat rodent diet, SF-01-14 
    ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 
                     Ingredient                                                                  Content (g/kg food) 
    ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 
                    Casein                                                                              200                              
                    Sucrose                                                                            528.4 
                    Corn oil                                                                              10 
                    Cocoa butter                                                                     150 
                    Methionine                                                   3 
                    Choline chloride (50%, w/w)                                             10                     
                    DL-α-tocopherol                        10 
                    AIN-93M minerals                                                             10 
                    AIN-93M vitamins                                                             35 
                    Cellulose                                                                             51 
                     
                    Total           1000 




            
            
           







             
            2.3 High fat diet (HFD)-fed -STZ-induced diabetic rats 
Male SD rats were fed HFD, SF-01-14 (Table 2), consisting of 20% fat, 46% 
carbohydrate and 20% protein (w/w) (Glen Forrest Stock Feeders, WA, Australia).  
After 2 weeks on HFD, animals were administered streptozotocin (STZ, 50 mg/kg) 
intraperitoneally.  Diabetes in the rats was identified by measuring fasting serum 
glucose concentration 72-h after injection of STZ. Rats with a serum glucose level 
above 300 mg/dL were selected for experiments. 
 
           2.4 STZ-induced diabetic C57BL/6J mice 
Male C57BL/6J mice were administered with streptozotocin (STZ, 100 mg/kg) 
intraperitoneally.  Animals had free access to food and water after STZ injection. 
Diabetes in the mice was identified by polydipsia, polyuria and by measuring 
fasting serum glucose concentration 72-h after injection of STZ. Mice with a 
serum glucose level above 300 mg/dL were selected for experiments. 
 
            2.5 HFD-induced diabetic C57BL/6J mice 
Male C57BL/6J mice were fed with HFD, SF-01-14, for 8-10 weeks to develop 
diabetes similar to NIDDM in humans (Shafrir, 2003). Diabetes in the mice was 
identified by measuring fasting glucose concentration after 10 weeks of feeding 
HFD. Mice with a serum glucose level above 250 mg/dL were selected for 
experiments. 
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            2.6 Determination of blood glucose by the glucose assay kit  
Glucose is first oxidized to gluconic acid and hydrogen peroxide. This reaction is 
catalyzed by glucose oxidase. The hydrogen peroxide formed reacts in the presence 
of peroxidase with 4-aminoantipyrine and p-hydroxybenzene sulfonate to form 
quinoneimine dye, with an absorbance maximum at 505 nm. The intensity of the 
color produced is directly proportional to the glucose concentration in the sample 
(Trinder, 1969).  The serum glucose concentration was expressed as mg/dL. 
 
2.7 Determination of total cholesterol by the Cholesterol (TG) reagent kit 
Cholesterol esterase in the reagent solution cleaves cholesterol esters in the serum 
to release cholesterol and free fatty acids. The free cholesterol and the enzyme-
liberated cholesterol are then oxidized by cholesterol oxidase to form cholestenone 
and hydrogen peroxide (H2O2). The peroxidase catalyses the reaction between the 
H2O2, 4-aminophenazone and phenol to form a pink complex [4-(p-benzo-quinone-
monoimino)-phenazone].  To estimate TC concentration, 1 ml reagent solution was 
added to 10 µl sample in 10 mm X 75 mm disposable tubes, mixed and then 
incubated at ambient temperature (25o C) for 10 min. The absorbance was read at 
500 nm within 1 hour. The cholesterol concentration was calculated according to 
the formula: 
            TC concentration (mg/100 mL) = 575 X (OD 500) sample 
The serum TC concentration was expressed as mg/dL. 
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2.8 Determination of serum high density lipoprotein cholesterol (HDL-C) by 
the HDL-cholesterol kit (CHOD-PAP method) 
To 100 µL of serum was added 250 µL of precipitating solution (0.55 mmol/L, 
phosphotungstic acid and 25 mmol/L, MgCl2) in order to precipitate chylomicrons, 
very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein 
cholesterol (LDL-C). The mixture was vortex-mixed and left to stand for 10 min at 
ambient temperature before centrifugation for 15 min at 1500 g. The HDL-C in the 
supernatant was determined for its cholesterol content as previously described for 
TC. The serum HDL-C concentration was calculated using the formula: 
HDL-C concentration (mg/100 mL) = 219.2 X (OD500) sample 
The serum HDL-C concentration was expressed as mg/dL. 
 
2.9 Determination of serum triglycerides by the Peridochrom® Triglyceride 
(TC) reagent 
An aliquot (1.0 mL) of reagent solution was added to 10 µL of sample, vortex-
mixed and incubated at 25 oC for 10 min before reading the absorbance at 500 nm. 
The TG in the sample was hydrolysed by lipase to liberate free fatty acid and 
glycerol. Glycerol kinase in the reagent converted glycerol to glycerol-3-
phosphate, which in turn was oxidized by glycerol phosphate oxidase to form 
dihydroxyacetone phosphate and H2O2.  Peroxidase would then catalyse the 
enzymatic reaction of H2O2 with 4-aminophenazone and 4-chlorophenol to form 
the pink 4-(p-bezoquinone-mono-imino)-phenazone, which absorbs at 500 nm. 
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            The following was used to calculate TG concentration: 
TG concentration (mg/100 mL) = 760 X (OD500) Sample 
The serum TG concentration was expressed as mg/dL. 
            
            2.10 Determination of low density lipoprotein cholesterol (LDL-C) 
The LDL-C was determined by the Friedewald’s formula (Friedewald et al., 1972). 
LDL-C = TC– HDL-C – TG/5 
The LDL-C concentration was expressed as mg/dL. 
 
2.11 Determination of anti-atherogenic index (AAI) 
A low level of circulating HDL-C is a surrogate marker for an atherogenic 
metabolic situation which is commonly known as the metabolic syndrome and 
several strands of evidence indicate that at a low level of circulating high density 
lipoprotein may be causally related to the development of atherosclerosis 
(Fogelberg et al., 1990; Brunzell et al., 2003). Hence, the AAI was calculated by 
the following formula; 
AAI = HDL-C/TC- (HDL-C) X 100 
            
            2.12 Serum insulin assay by ELISA kit 
Serum insulin level was measured by an enzyme-liked immunosorbent assay 
(ELISA) procedure using Mercodia rat insulin ELISA kit. Briefly, the solid phase 
two-site enzyme immunoassay is based on the direct sandwich technique in which 
two monoclonal antibodies are directed against separate antigenic determinants 
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(epitopes) on the insulin molecule. During incubation, insulin in the sample reacts 
with peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies 
bound to the microtitration well. After washing three times, unbound enzyme 
labeled antibody was removed. The bound conjugated insulin was detected by 
reacting with 3, 3’, 5, 5’-tetramethylbenzidine. The reaction was stopped by adding 
acid to give a colorimetric end-point and optical density was measured with a 
microplate autoreader (Bio-tek Instrument Inc., USA) at a wavelength of 450 nm. 
The serum insulin was expressed as µg/L. 
 
2.13 Serum leptin assay by ELISA kit 
Leptin level was also detected by an ELISA assay using a kit.  Optical density was 
measured with the same microplate autoreader as above and at a wavelength of 
450 nm. The serum leptin was expressed as pg/L. 
 
2.14 Pancreatic insulin assay 
According to the method of Portha et al. (1979), the pancreas was homogenized for 
1 min by ultrasonic disintegration at 4°C in acid-alcohol solution (75% ethanol, 
1.5% 12 mol/L HCl, 23.5% distill water). The homogenate was left to stand 
overnight at -20°C and then centrifuged the next morning at 6000 g for 15 min. 
The insulin concentration of the supernatants was determined by the method 
previously described (Method 2.12.). The results were expressed as ng/g wet 
weight of tissue.    
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2.15 Estimation of liver glucose-6-phosphatase (Glc-6-Pase) activity  
Glc-6-Pase activity was assayed according to Baginsky et al. (1974) by estimation 
of inorganic phosphate liberated from glucose-6-phosphate (Glc-6-P). For this 
assay, 1 g of frozen liver tissue was homogenized in ice-cold sucrose solution with 
a Polytron homogenizer. The homogenate was centrifuged sequentially at 11,000 g 
for 30 min, then at 105,000 g for 1 h using an ultracentrifuge (Beckman L8-70, 
Beckman Instruments, Inc., CA, USA). The solid pellet was resuspended in ice-
cold sucrose/EDTA solution and used as the source of the enzyme. Tubes were 
divided into samples, blanks and standard.  To each were added 0.1 mL of 
sucrose/EDTA buffer (0.25 M/L mM, pH 7.0), 0.1 mL of Glc-6-P (100 mM), and 
cacodylate buffer solution. This was followed by the addition of 0.1 mL of sample 
to the sample tube, 0.1 mL of sucrose/EDTA solution to the blank and 0.1 mL of 
different concentration of K2HPO4 (0.5 mM, 1 mM, 1.5 mM and 2 mM) to the 
standard tube. All tubes were incubated at 37°C for 15 min and the enzyme activity 
was then terminated by adding 2 ml TCA/ascorbate (10%/2%). The tubes were 
centrifuged at 3000 g for 10 min. To 1.0 mL of this clean supernatant were added 
0.5 ml ammonium molybdate (1%) and 1 mL of Na-arsenite/Na-citrate (2%/2%). 
The tubes were then allowed to stand for 15 min at room temperature and 
absorbance was read at 840 nm. The mount of inorganic phosphate liberated by the 
enzyme was calculated by comparing with absorbance values of the standard. 
Enzyme activity was expressed in mmol of Pi liberated/min/mg of protein. 
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            2.16 Liver glycogen assay 
Liver glycogen content was measured according to the method of Murat and 
Serfaty (1974). Weighed frozen tissue was placed in chilled citrate buffer (0.1 M, 
pH 4.5) and homogenized with a polytron homogenizer (Kinematica, GmbH, 
Switzerland). After measuring free glucose in the homogenate, amyloglucosidase 
was added to the homogenate at a concentration of 1 mg enzyme/mL of 
homogenate and incubated overnight (16 h) at room temperature. The glycogen 
content of the liver samples was estimated by comparing glucose liberated from 
the tissue with a standard curve obtained by treating known amounts of glycogen 
with amyloglucosidase enzyme. The liver glycogen content was expressed as mg/g 
wet tissue. 
 
2.17 Measurements of malondialdehyde (MDA) levels in liver, kidney and 
pancreas by the thiobarbituric acid (TBA) method 
Malondialdehyde (MDA), an end product of lipid peroxidation, reacts with 
thiobarbituric acid (TBA) to form a colored substance. Measurement of MDA by 
TBA reactivity is the most widely used method for assessing lipid peroxidation. 
Kidney, liver and pancreas samples were minced finely and homogenized by a 
Polytron homogenizer in ice-cold 1.15% KCl to make a 25% (w/v) (kidney and 
liver) or 20% (w/v) (pancreas) homogenate. The determination of thiobarbituric 
acid reactive substance (TBARS) values was performed by the method of 
Uchiyama and Mihara (1978). To 0.1 mL of the homogenate, 0.2 mL of 8.1% 
dodecyl sulfate sodium salt (SDS), 1.5 mL of 1% phosphoric acid, 0.2 mL distilled 
water and 1.0 mL of 0.6% 2-TBA were added. The mixture was heated in a boiling 
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water-bath for 45 min. After the reaction, the mixture was cooled in an ice-bath; 
the cold TBA reactants were extracted with 4.0 mL of n-butanol. After 
centrifugation at 1000 g for 5 min, the optical density of the n-butanol layer was 
determined at 535 nm. The TBARS values in kidney and liver were expressed as 
nmol of MDA per 25 mg wet tissue while the values of pancreas were expressed as 
nmol of MDA per mg wet tissue.  
            
           2.18 Protein determination 
The protein concentration was initially determined using Lowry’s method. Later it 
was replaced by Bradford method. 
            
            2.18.1. Lowry’s method 
This is the most widely used method for quantitative determination of protein 
concentration and is sensitive to the level of 10 µg of protein per mL. Reaction of 
the phenolic moiety of tyrosine in protein occurs with Folin-Ciocalteau reagent, 
which contains phosphomolybdic/tungstic acid mixture produces a blue/purple 
colour with absorption maximum around 660 nm. Additionally, the use of a copper 
reagent enhances the colour formation by chelating with the peptide bonds and 
allowing for efficient electron transfer to the chromophore formed (Lowry et al., 
1951). The protein content of the sample was expressed as mg/dL. 
 




            2.18.2 Bradford’s method      
The protein content in the sample was determined by the method of Bradford 
(1976), using the Bio-Rad protein assay reagent.    The protein content in the 
samples (mg protein/mL sample) was determined by spectrophotometry according 
to the method of Bradford (1976) and using the Bio-Rad protein assay reagent.  
This method is a dye (Coomassie blue)-binding assay in which differential color 
changes occur in dye in the presence of various concentrations of protein.  The dye 
binds primarily to basic and aromatic amino acid residues, especially arginine. The 
maximum absorbance wavelength for an acidic solution of Coomassie® Brilliant 
Blue G-250 dye shifts from 465 nm to 595 nm when binding to protein occurs.  
The absorbance of the samples was determined by spectrophotometry at 595 nm 
and the protein content was expressed as mg/dL.  
 
            2.19 Determination of the microsomal cytochrome P450 content 
            2.19.1 Preparation of liver microsomes 
Liver microsomes were prepared by the ultra-centrifugation method (El Defrawy 
et al., 1974). Rat liver (2g) was homogenized in ice cold 1.15% KCl (20 mL) using 
a glass Potter-Elvejhem homogenizer. The homogenate obtained was centrifuged 
at 10,000g for 10 min at 4oC. The resulting supernatant obtained was recentrifuged 
at 100,000g for further 45 min at 4oC.  The microsomal pellet was resuspended in a 
volume of glycerol buffer [200 mM potassium phosphate buffer, pH 7.4; 50% 
(v/v) and 1.15% (w/v) potassium chloride (5:8:7)] equivalent to twice the liver 
weight. The pellet was further homogenized with 7 strokes of the pestle after 
which aliquots of the microsomal suspension were stored at – 70oC. 
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          2.19.2 Assay of liver microsomal cytochrome P450 content 
An aliquot of microsomal preparation of 1 mg protein/mL was obtained by adding 
0.5 mL of 1M potassium phosphate buffer and the required volume of 1.15% KCl. 
A modified technique (Omura and Sato, 1964)) was adopted in this assay to 
eliminate the absorption peak at 420 nm due to contamination by hemoglobin in the 
sample.  The microsomal preparation was placed in two cuvettes and initially 
saturated with carbon monoxide. A small amount of sodium dithionite (not more 
than 2 mg) was added to the sample cuvette only.  The microsomal P450 content was 
then determined from the difference in absorbance values between the dithionite 
reduced and control microsomal preparations using a Shimadzu UV-dual-beam 
spectrophotometer. The molar extinction co-efficient of microsomal P450 at the λ 
max of 450 nm was 91 mM-1 cm-1. The liver cytochrome P450 content was expressed 
as nmol/mg of protein. 
 
 2.20 High performance liquid chromatography 
High performance liquid chromatography (HPLC) analysis of ABe, AF, BuF 
standard niacin (98% pure), was performed on Shimadzu Class LC-10 (version 
1.64) with computer control. The system consists of a dual reciprocating plunger 
solvent delivery module connected to a degasser, an automatic injector with 1 µL 
sample loop. A 250 mm x 4.6 mm stainless steel SYNERGI 4 u hydro- RP 80A 
(Part No: 00G-4375-E0) column (Phenomenex) was used. Detection was made 
using photodiode array as the photo-detector element. The eluting solvents, HPLC 
grade acetonitrile and deionized water, were filtered through 0.45 µm filters, 
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mixed then placed into screw capped reagent bottles. Separation of samples was 
achieved using a linear gradient of acetonitrile (0 to 100%).  The separation 
temperature was kept constant at 50 oC, flow rate and sample volume were set to 
1.0 mL/min and 10 µL, respectively. The separations were monitored 
simultaneously with ultraviolet detection in the wavelength range of 215 nm to 280 
nm.  The retention time of the main peak of standard niacin was compared to those 
of ABe, AF, and BuF. 
             
            2.21 Metal analysis by atomic absorption spectrophotometer 
Perkin-Elmer 1100B Atomic Absorption Spectrophotometer, a microcomputer-
controlled atomic absorption/emission spectrometer, was used for ppm level 
detection of metal elements of ABe, AF and BuF by the flame technique. The 
sample was heated to a high temperature in a flame. After evaporation of the 
solvent, the flame dissociates chemical bonds and releases free metal atoms which 
absorb light that is characteristic for individual elements. The band wavelengths at 
which each element absorbs is narrow and almost unique.   The unexcited atoms 
absorb light, which raises the valence electron (s) to an excited state; as a result of 
this absorption, the intensity of the original light is reduced. The amount of light 
absorbed is proportional to the concentration of the element present (Sawyer et al. 
1984).   
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            2.22 Statistical analysis 
The results are presented as means ± SEM. The statistical methods used to analyse 
the data in this study were unpaired Student’s t-test (two-tailed) and two-way 
analysis of variance (ANOVA) using MS-Excel software program. Comparisons 














































Experiment 1:  Effects of A.bilimbi leaf extract on blood glucose and lipids in 
STZ-diabetic rats 
            1.1 Aims  
In the present study, we evaluated the antidiabetic effects of an ethanolic extract of 
A.bilimbi leaves (prepared according to Method 2.1.1) on glucose tolerance in 
normal and STZ-induced SD diabetic rats and fasting blood glucose and serum 
lipid profile in STZ-diabetic SD rats, and compared its effects with those of 
metformin, a biguanide used as an antidiabetic agent. 
 
              1.2 Experimental procedure 
            1.2.1 The OGTT in normal and STZ - diabetic SD rats 
Prior to OGTT, male SD rats were fasted for 16 h.  Distilled water (control), a 
reference drug metformin (500 mg/kg), or each of three different doses of ABe 
(125 mg, 250 mg, and 500 mg/kg) was then orally administered to groups of 5 rats 
each.  Thirty minutes later, glucose (3 g/kg) was orally administered to each rat 
with a feeding syringe (Al-awadi et al., 1985).  Blood samples were collected from 
the tail vein by tail milking at - 30 min (just before the ABe and metformin 
administration), 0 (just before the oral administration of glucose), 60, 120, and 180 
min after glucose load for the assay of glucose.  The OGTTs were performed in 
STZ-diabetic rats using the same procedure as described for the normal rats.  Six 
animals were used for distilled water (control), metformin (positive control) and 
ABe-treated groups. 
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            Figure 5.  OGTT in normal SD rats.  
Values are expressed as the mean ± SEM for 5 rats in each group. The % change in 
blood glucose at 60, 120, and 180 min was calculated from the corresponding 0-h 
value (just before the oral administration of glucose) in each group.  
 














            1.2.2 Repeated administration of ABe in STZ-diabetic SD rats 
One week after STZ induction of diabetes in male SD rats, the fasting blood 
glucose levels were measured. The hyperglycemic rats (blood glucose >350 mg/dl) 
were divided on day zero into three groups (each with 6 rats).  The fasting blood 
glucose level (FBG), total cholesterol (TC), triglycerides (TG), HDL-cholesterol 
(HDL-C), and LDL-cholesterol (LDL-C) concentrations were also measured on 
day zero.  Distilled water, metformin (500 mg/kg) and ABe (125 mg/kg) were then 
administered orally twice a day to control, positive control and the treatment 
groups respectively for 2 weeks.  Body weight, food and water intakes were 
monitored daily for 2 weeks.  On day 15, after 16 h fasting, the rats were 
decapitated and the blood was collected for estimation of the FBG, TC, TG, HDL-
C and LDL-C. The organs such as liver and kidney were isolated, weighed and 
stored at -70°C for the assay of hepatic cytochrome P450 and thiobarbituric acid 
reactive substances (TBARS) in both liver and kidney 
 
1.3 Results and discussion 
1.3.1 Dose response effect of ABe on glucose tolerance in normal and STZ –    
diabetic rats                                       
The blood glucose levels of the normal rats reached a peak at 60 min after the oral 
administration of glucose and gradually decreased to pre-glucose load level 
(Figure 5).  Of the three different doses viz., 125 mg, 250 mg, and 500 mg/kg, the 
lowest dose caused a significant attenuation in the blood glucose at 180 min 






















Figure 6.  OGTT in diabetic SD rats.   
Values are expressed as the mean ± SEM for 6 rats in each group.  The % change 
in blood glucose at 60, 120, and 180 min was calculated from the corresponding 0-
h value (just before the oral administration of glucose) in each group.  




















































also produced a significant decrease (P<0.01) in blood glucose level at 180 min 
after the administration of the oral glucose load. 
 
In the diabetic rats, fasting blood glucose levels were 4-5 times higher than that of 
the   normal SD rats. ABe at a dose of 125 mg/kg produced a significant 
attenuation in the blood glucose (P<0.05) at 120 min and 180 min (P<0.01) after 
the oral glucose load (Figure 6). No significant attenuation was observed in the rats 
administered 250 mg of ABe/kg, even at 180 minutes.  However, ABe at a dose of 
500 mg/kg caused a significant attenuation (P<0.01) in the blood glucose only at 
180 min when compared to the vehicle-treated group.  Metformin (500 mg/kg) 
caused significant attenuation at 60 min (P<0.001), 120 min (P<0.01) and 180 min 
(P<0.01) when compared to the vehicle-treated group.  Of the three doses of ABe 
tested, the lowest dose (125 mg/kg) appeared to be most effective in improving 
glucose tolerance (P<0.01).  Hence this dose was selected for the 2- week study. 
 
1.3.2 Effects of 2-week administration of ABe (125 mg/kg) and metformin on 
blood glucose and lipids in STZ-diabetic rats              
The body weights in the ABe and the metformin-treated group were increased 
significantly (P<0.001) on day 14 when compared with the vehicle-treated group.  
The food intake was significantly lowered in the ABe and metformin-treated group 
(P<0.001) when compared with the vehicle-treated group.  Similarly, water intake 







Table 3. Body weight, water and food intakes in STZ-diabetic rats before and 
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Figure 7.  Effects of ABe treatment on FBG and TC levels in STZ-diabetic rats. 
FBG and TC levels in diabetic rats before and after daily oral treatment with vehicle 
(distilled water), ABe (125 mg/kg) and metformin (500 mg/kg) for 2 weeks. 
Columns represent the mean ± SEM (n= 6). 
 
*P<0.05 compared against control (Student’s t-test). 





















































As shown in Figure 7, the daily administration of  ABe (125 mg/kg) twice a day 
for 14 days in STZ-diabetic SD rats caused a significant reduction in blood glucose 
level when compared with the vehicle-treated control (P<0.01) rats and day zero 
value (P<0.05).  Similarly, repeated administration of metformin (500 mg/kg) 
twice a day for 14 days caused a significant reduction (P<0.01) in the blood 
glucose level in STZ-diabetic SD rats when compared to vehicle and day zero 
values.  There was a significant decrease in serum TG (P<0.05) and a significant 
increase in HDL-C (P<0.05) in the ABe-treated SD rats (Figure 8) when compared 
to the vehicle-treated control SD rats. However, ABe did not decrease serum 
cholesterol and LDL-C concentrations significantly (P>0.05).  The daily 
administration of metformin to STZ-diabetic SD rats caused a significant decrease 
in the serum TG (P<0.01) when compared to the vehicle-treated control rats.  
Metformin, however, did not decrease serum cholesterol and LDL-C 
concentrations (Figure 8).  It also failed to increase serum HDL-C concentration. 
The AAI (refer to Method 2.11.) was significantly increased in the ABe-treated 
group (P<0.001) when compared to the vehicle-treated group of rats (Figure 9).  
However, there was no significant difference in the AAI of the Metformin-and the 










































     Figure 8.  Effects of ABe treatment on serum TG and LDL-C in STZ-diabetic rats. 
Serum TG and LDL-C levels in diabetic rats before and after daily oral treatment with 
vehicle (distilled water), ABe (125 mg/kg) and metformin (500 mg/kg) for 2 weeks. 
Columns represent the mean ± SEM (n= 6). 
 





































































            Figure 9.  Effects of ABe treatment on HDL-C and AAI in STZ-diabetic rats. 
HDL-C level and AAI of diabetic rats before and after daily oral treatment with 
vehicle (distilled water), ABe (125 mg/kg), and metformin (500 mg/kg) for 2 
weeks. Columns represent the mean ± SEM (n= 6). 
 




















































Table 4.  Liver cytochrome P450 content and lipid peroxidation level in the kidney and 
liver of STZ-diabetic rats after 2 weeks of oral treatment twice a day with vehicle, 




*P<0.05 compared with vehicle-treated rats ((Student’s t-test). 
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   1.01 ± 0.03 * 
 
 










2.8 ± 0.13 
 
 










3.3 ± 0.25 ** 
 55
As shown in Table 4, there was no significant difference in the hepatic microsomal 
cytochrome P450 content between ABe- and vehicle-treated control STZ-diabetic 
SD rats (P>0.05).  However there was a significant reduction in the hepatic 
microsomal cytochrome P450 content in the metformin-treated group when 
compared to the vehicle-treated group (P<0.05).   
 
The TBARS levels were significantly reduced in the kidneys of both ABe- and 
metformin-treated STZ-diabetic SD rats (P<0.01). However there was no 
significant difference in TBARS levels in the livers of both ABe- and metformin-
treated diabetic rats when compared to the vehicle-treated control rats.  
                                                 
The single high dose STZ-induced diabetic rat is one of the animal models of 
human IDDM or type I diabetes mellitus. In this model, diabetes arises from 
irreversible destruction of the β-islet cells of the pancreas, causing degranulation 
or reduction of insulin secretion (Junod et al., 1969).  Our present studies show that 
ABe demonstrates a definite hypoglycemic, hypotriglyceridemic, anti-atherogenic, 
and anti-lipid peroxidative properties in STZ-diabetic rats after 2 weeks of 
treatment.  The hypoglycemic activity of ABe was observed at the lowest dose 
(125 mg/kg) in normal as well as STZ-diabetic rats and was similar to the action of 
metformin.  Metformin, a biguanide, does not induce the secretion of insulin from 
the β-islet cells of pancreas, but increases glucose utilisation in the extra-hepatic 
tissues, reduces hepatic gluconeogenesis (Bailey, 1992) and increases the 
expression of insulin receptors in the liver plasma membranes (Kanigur-Sultuybek 
et al., 1995).  Since ABe reduced blood glucose potently in the STZ-diabetic SD 
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rats like metformin, it may have hypoglycemic principle(s) that are similar in 
action to metformin. 
 
 The daily administration of ABe (125 mg/kg) and metformin (500 mg/kg) to STZ-
diabetic rats twice a day for two weeks caused a statistically significant reduction 
in food and water intakes, and an increase in the body weight of STZ- diabetic rats.  
This could be the result of improved glycemic control induced by the compounds. 
ABe might reduce TG by decreasing the serum non-esterified fatty acids (NEFA) 
in the STZ-diabetic rats similar to masoprocol (nordihydroguaiaretic acid), a pure 
compound isolated from Larrea tridentata (Reed et al., 1999).  Since ABe 
increased HDL-C, it significantly increased the AAI.  ABe thus has the potential to 
prevent the formation of atherosclerosis and coronary heart disease which are the 
secondary diabetic complications of severe diabetes mellitus (Fontbonne et al., 
1989).  In contrast, metformin failed to increase the HDL-C level and did not 
increase the AAI.  However it has been reported that metformin can reduce blood 
lipid parameters in non-diabetic patients with coronary heart disease (Carlsen et 
al., 1996).  Hence, ABe may contain a hypolipidemic principle(s), which could act 
in a way different from that of metformin.  The cytochromes are the primary 
system (phase Ι detoxification enzymes) responsible for chemical defense in 
animals (Elizabeth Gillam, 1998).  The cytochrome P450 content in the liver has 
been found to be increased in diabetic animals (Lucas et al., 1998).  The reduction 
in insulin levels in the diabetic state also causes an increase in the level of 
cytochrome P450 enzymes (Woodcroft and Novak., 1997).   
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In this study, cytochrome P450 content of the ABe-treated group was similar to that 
of the vehicle-treated group.  However, a significant reduction (P<0.05) was found 
in the metformin-treated group.  As metformin is not known to reduce insulin 
levels, mechanism by which it reduces the cytochrome P450 content is not known. 
 
The hyperglycemia in STZ-treated rats leads to the formation of hydrogen 
peroxide, which subsequently generates free radicals such as O2− and OH°.  These 
reactive compounds can cause peroxidation of lipids, resulting in the formation of 
hydroperoxy fatty acids and endoperoxides.  This increases the formation of 
malonaldehyde (MDA) and thromboxane-B2 (TxB2). The accumulation of TxB2 
together with thromboxane-A2 (TxA2) can cause platelet aggregation and promote 
thrombosis (Sushil Jain et al., 1998).  Since ABe has the ability to reduce the 








Experiment 2: Evaluation of the anti-diabetic effects of semi-purified 
fractions of ABe in a rat model of type 1 diabetes 
            2.1 Aims  
In the present study, the aim was to evaluate the antidiabetic effects of semi-
purified fractions of ABe in STZ-induced diabetic rats compared with metformin. 
             
            2.2 Experimental procedure 
2.2.1 The OGTT in STZ – diabetic rats using the semi-purified fractions of 
ABe 
Prior to OGTT, rats were fasted for 16 h.  Distilled water (control), four different 
fractions of ABe viz. AF, BuF, EF and HF each at a dose of 125 mg/kg body 
weight and the reference drug, metformin, at a dose of 500 mg/kg body weight 
were orally administered to groups of 5-6 rats each.  Thirty minutes later, glucose 
(3 g/kg) was orally administered (Al-Awadi et al., 1985) to each rat with a feeding 
syringe.  Blood samples were collected from the tail vein by tail milking at – 30 
min (just before the administration of distilled water, fractions of ABe and 
metformin in respective groups), 0 (just before the oral administration of glucose), 





















Figure 10.  The OGTT in STZ-diabetic rats using the semi-purified fractions of 
ABe.  
The graph represents the mean percentage changes in blood glucose concentration 
over – 30 min level in Vehicle (565 ± 28), Aqueous Fraction [AF] (608 ± 42), 
Butanol Fraction [BuF] (540 ± 51), Ethyl acetate Fraction [EF] (487 ± 11), and 
Hexane Fraction [HF] (448 ± 19) of ABe, each at a dose of 125 mg/kg and 
Metformin (603 ± 30) –treated (500 mg/kg) diabetic rats, while bars represent 
SEM (n = 6).  The blood glucose concentration (mg/dL) of each group at –30 min 
is given in brackets. 
  *P<0.05 BuF-treated group vs vehicle-treated group (Student’s t-test). 
**P<0.01 Metformin-treated group vs vehicle-treated group (Student’s t-test). 
            #P<0.05 AF-treated group vs vehicle-treated group (Student’s t-test). 






















































2.2.2 Twice daily oral administration of AF (125 mg/kg) and BuF (125 mg/kg) 
for two weeks in STZ-diabetic rats 
One week after STZ induction of diabetes in male SD rats, the fasting blood 
glucose levels were measured. The hyperglycemic rats (blood glucose >350 mg/dl) 
were divided on day zero into four groups (each with 6 rats).  The fasting blood 
glucose level was measured on day zero at 9.00 am.  Distilled water, AF (125 
mg/kg), BuF (125 mg/kg) and metformin (500 mg/kg) were then administered 
orally twice a day at 9.00 am and 9.00 pm to diabetic control, treatment and 
positive control groups respectively for 2 weeks.  Body weight, food and water 
intakes were monitored every day between 9.00 and 10.00 am for 2 weeks.  On the 
15th day, after 16 h fasting, the rats were decapitated and blood was collected at 
9.00 am for estimation of the fasting blood glucose.  The organs, liver and kidney, 
were isolated, weighed and stored at -70°C for the assay of hepatic Glc-6-Pase, 
glycogen, cytochrome P450 and TBARS contents. 
 
2.3 Results and discussion 
In the OGTT (Figure 10), AF (125 mg/kg) caused a significant hypoglycemic 
effect within 30 minutes after oral administration to STZ-diabetic rats.  AF also 
produced a significant attenuation (P < 0.01) in blood glucose level at 0 min, 120-
min and 180 min when compared with vehicle control. BuF (125 mg/kg) had no 
significant effect on blood glucose at 0 min, but produced a significant attenuation 
(P < 0.05) at 120 and 180 minutes after oral administration. The other two-





Table 5. Body weight, water and food intakes in STZ-diabetic rats before and after 
oral treatment with vehicle, AF, BuF, and metformin twice a day for 2 weeks  
 
 








 Body weight (g) 
 (mean ± SEM) 
  Water (mL/rat/day) 
    ( mean ± SEM) 
    Food (g/rat/day) 
    ( mean ± SEM) 
 
Treatment group 
(n = 6) 
 
Before After Before After Before After 
 
       Control 
           
 




         BuF 
 
 
     Metformin 
223 ± 3 
225 ± 5 
221 ± 9 




241 ± 9 
166 ± 10 
144  ± 19
145 ± 10 
153 ± 7 
195 ± 10 
158 ± 19* 
168 ± 5* 
145 ± 6* 
 
32 ± 5 
33 ± 3 
41 ± 3 
40 ± 2 
50 ± 6 
43 ± 4* 
46 ± 1* 
43 ± 2* 
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In this type I model of diabetes, insulin is markedly depleted, but not completely 
absent (Junod et al., 1969).  Although insulin has become one of the most 
important therapeutic agents known to medicine, there is a continuing effort to find 
insulin substitutes, secretagogues, or sensitizers from synthetic or plant sources for 
the treatment of diabetes. Over 150 plant extracts and some of their active 
principles including flavonoids are known to be used for the treatment of diabetes 
mellitus (Olajide et al., 1999). The present study revealed that the semi-purified 
fractions, AF and BuF, of ABe have potent hypoglycemic property when given for 
2 weeks to STZ-diabetic rats. Tan et al (1996) reported the hypoglycemic 
properties of both aqueous and ethanolic extracts of the leaves of A.bilimbi in STZ-
diabetic Wistar rats when these were administered intraperitoneally at doses of 100 
mg/kg and 300 mg/kg respectively.   
 
Although the body weight of the rats did not differ significantly (Table 5), there 
was about 8% increase in the AF treated group and 13% increase in the BuF-
treated group when compared to the vehicle-treated control group. However, the 
food and water intakes of AF- and BuF-treated diabetic rats were significantly 
different as in the metformin-treated group when compared to the vehicle-treated 
group. Similar effects were reported for other hypoglycemic agents such as 








































Figure 11. Effects of AF and BuF treatment on FBG and insulin levels in STZ-
diabetic rats. 
The blood glucose and insulin levels were measured on day 0, day 7, and day 14 at 
9.00 a.m. after 16 hour fast in the vehicle (distilled water), AF (125 mg/kg), BuF 
(125 mg/kg) and metformin (500 mg/kg)-treated STZ-diabetic rats. Columns 
represent the mean ± SEM (n= 6). 
 
*P<0.05 compared with the diabetic untreated rats (Student’s t-test).  
**P<0.01 compared with the diabetic untreated rats (Student’s t-test). 
































   *   **

















































AF caused a significant (P<0.01) time-dependent hypoglycemic effect after twice-
daily oral administration at a dose of 125 mg/kg for 7 and 14 days (Figure 11). BuF 
also showed a significant (P<0.05) hypoglycemic property on day 7 as well as on 
day 14 compared to the vehicle-treated control group. However, BuF did not cause 
a statistically significant reduction in blood glucose on day 7 and 14 when 
compared to day 0 value (of BuF-treated group). This indicates that the AF is 
better than BuF in controlling the blood glucose of diabetic animals. The serum 
insulin level in the AF-treated group was significantly higher on day 14 compared 
to both the control (P<0.05) and day zero levels (P<0.05) (Figure 11). On the other 
hand, the serum insulin level in the BuF-treated group was significantly higher on 
both day 7 (P<0.05) and day 14 (P<0.05) when compared to its day zero value.  
 
The elevation in serum insulin in the AF- and BuF-treated STZ-diabetic rats could 
either be due to the presence of insulinotropic substances in the fractions, (which 
induce the intact functional β-cells to produce insulin), or the protection of the 
functional β-cells from further deterioration so that they remain active and produce 
insulin. However, except for the level in AF-treated group on day 14, the insulin 
levels were well below the normal insulin level in control rats, suggesting that they 
may not be sufficient to lower the blood glucose to its normal level in the STZ-
diabetic rats. Our results indicate a possible insulin-releasing action of ABe in 
STZ-diabetic rats. Similarly the extracts of Medicago sativa (Gray and Flatt, 1997), 
Eucalyptus globulus (Gray and Flatt, 1998) and Sambucus nigra (Gray et al., 2000) 




























Figure 12. Effects of AF and BuF treatment on hepatic Glc-6-Pase activity in STZ-
diabetic rats. 
Hepatic Glc-6-Pase activity after 2- week oral treatment with vehicle (distilled water), 
AF (125 mg/kg), BuF (125 mg/kg) and metformin (500 mg/kg). Columns represent the 
mean ± SEM (n= 6). 
 

















































Glc-6-Pase activity (Figure 12) in the liver was significantly reduced (P<0.05) in 
both AF-and metformin-treated groups when compared to the vehicle-treated 
diabetic control group. However, there was no significant change in the activity of 
BuF–treated group.  Glc-6-Pase catalyzes the final step in glucose production by 
the liver and kidney. STZ has been reported to increase the expression of Glc-6-
Pase mRNA, which contributes to the increased Glc-6-Pase activity in diabetes 
mellitus (Liu et al., 1994). Overproduction of glucose by the liver is the major 
cause of fasting hyperglycemia in both insulin-dependent and non-insulin-
dependent diabetes mellitus.   90% of partially pancreatectomized diabetic rats 
have a >5-fold increase in the mRNA and a 3-4-fold increase in the protein level of 
the catalytic subunit of hepatic Glc-6-Pase. Prolonged hyperglycemia may thus 
result in overproduction of glucose via increased expression of this protein 
(Massillon et al., 1996). Normalization of the plasma glucose concentration in 
diabetic rats with either insulin or the glycosuric agent, phlorizin, normalized the 
hepatic Glc-6-Pase mRNA and protein within approximately 8 h. However, 
phlorizin failed to decrease Glc-6-Pase gene expression in diabetic rats when the 
fall in the plasma glucose concentration was prevented by glucose infusion. These 
data indicate that in vivo gene expression of Glc-6-Pase in the diabetic liver is 
regulated by glucose independently of insulin.  AF-fraction, like the biguanide 
drug, metformin, controls the increase in blood glucose in STZ-diabetic rats by 
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decreasing the activity of Glc-6-Pase in the liver. This could be one of the 
mechanisms for the suppression of blood glucose concentration in the diabetic rats. 
Other workers have also reported that extracts of some plants such as Zizyphus 
spina-christi significantly reduced serum glucose level, liver phosphorylase and 
Glc-6-Pase activities, and significantly increased serum pyruvate level and liver 
glycogen content after 4 weeks of treatment (Glombitza et al., 1994). Similarly, 60 
% ethanolic extract of Coccinia indica and 95 % ethanolic extract of Momordica 
charantia extracts were found to lower blood glucose by depressing its synthesis, 
on the one-hand, through depression of the key gluconeogenic enzymes, Glc-6-
Pase and fructose-1, 6-bisphosphatase (Fru-1, 6-P2ase) and on the other by 
enhancing glucose oxidation by the shunt pathway through activation of its 
principal enzyme, G6PDH (Shibib et al., 1993).  
 
The liver is an attractive target organ for insulin gene expression in type 1 diabetes 
as it contains appropriate cellular mechanisms of regulated gene expression in 
response to blood glucose and insulin.  The expression of the promoter of the Glc-
6-Pase gene in the liver is induced by glucose and suppressed by insulin (Chen et 
al., 2000). Insulin suppresses hepatic glucose production (HGP) in euglycemia by 
solely decreasing the Glc-6-P concentration; when combining hyperinsulinemia 
with hyperglycemia, the suppression of HGP involves the inhibition of the Glc-6-
Pase activity; and a sustained glucose-phosphorylation flux might be a crucial 
determinant in the inhibition of Glc-6-Pase and of HGP (Guignot and Mithieux, 
1999). The operation of Glc-6-Pase stems from the interaction of at least two 
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highly hydrophobic proteins embedded in the ER membrane, a heavily 
glycosylated catalytic subunit of molecular weight 36 kDa (P36) and a 46-kDa 
putative Glc-6-P translocase (P46). P36 gene expression is increased by glucose, 
fructose 2, 6-bisphosphate (Fru-2, 6-P2) and free fatty acids, as well as by 
glucocorticoids and cyclic AMP; the latter are counteracted by insulin. P46 gene, 
like P36 gene, expression is affected by glucose, insulin and cyclic AMP (Van de 
Werve et al., 2000). The insulinotropic effect of AF might play a crucial role in the 
control of hyperglycemia in STZ-diabetic rats. Insulin thus inhibits the activity of 
glucose-6-phosphatase in the liver of STZ-diabetic rats and thereby controls HGP. 
Hence the suppression of Glc-6-P hydrolysis could also be one of the reasons for 
the hypoglycemic effect of AF in STZ-diabetic rats. Similar effects were reported 























Figure 13. Effects of AF and BuF treatment on hepatic glycogen content in STZ-   
diabetic rats. Hepatic glycogen content after 2- week oral treatment with vehicle 
(distilled water), AF (125 mg/kg), BuF (125 mg/kg) and metformin (500 mg/kg).  
Columns represent the mean ± SEM (n= 6). 
 
Table 6.  Liver cytochrome P450 content and TBARS levels in the kidney and 
liver of STZ-diabetic rats after twice-a-day oral treatment for 2 weeks with 












         *P < 0.05 compared with vehicle-treated rats (Student’s t-test). 
TBARS level 
(nmol of malonaldehyde per 
25 mg of tissue) 








cytochrome P450    
content (nmol/mg 
protein) 












4.0 ± 0.2 
 
 
3.8 ± 0.1 
 
 
3.9 ± 0.2 
 
 
3.7 ± 0.2 
4.7 ± 0.3 
 
 
3.9 ± 0.2* 
 
 
4.0 ± 0.3 
 
 
3.7 ± 0.2* 
1.25 ± 0.04 
 
 
1.15 ± 0.04 
 
 
1.20 ± 0.06 
 
 































However, there was no significant difference in the level of hepatic glycogen 
content in AF, BuF and also metformin-treated rats compared to vehicle-treated 
rats although the hepatic glycogen content tended to be higher in the AF-treated 
group when compared to the control group (Figure 13). Similarly, Vanadate 
compounds have been shown to inhibit hepatic Glc-6-Pase activity, thereby 
reducing blood glucose levels in non-obese diabetic (NOD) mice. However no 
significant difference was found in the hepatic glycogen stores of the treated 
groups compared to control (Schulz, 1988).  The kidney TBARS in AF- and 
metformin-treated diabetic rats were significantly lower (Table 6, P < 0.05) than in 
the vehicle-treated rats.   On the other hand, the kidney TBARS value in BuF-
treated rats was not significantly different from that in the vehicle-treated rats. 
There was also no difference in liver TBARS values between AF-, BuF- and 
metformin-treated rats and vehicle-treated control rats.  The liver microsomal 
cytochrome P450 content was significantly lower in the metformin-treated rats when 
compared to that in the corresponding vehicle-treated rats.  However, there was no 
significant difference in the liver cytochrome P450 content in AF- and BuF-treated 











The level of increase in the hepatic cytochrome P450 content depends on the 
duration of diabetes (Barnett et al., 1994).Reduced insulin level in the diabetic state 
also causes an increase in cytochrome P450 content (Woodcraft et al., 1997). In this 
study, AF and BuF did not cause any change in the cytochrome P450 enzymes in the 
liver. However a reduction was found in the metformin-treated group.  
 
Hypoinsulinemia in diabetes increases the activity of fatty acyl coenzyme A 
oxidase, which initiates β-oxidation of fatty acids, resulting in lipid peroxidation 
(Bruch and Thayer, 1983). The enormous increase in lipid peroxidation leads to 
the alteration of the transbilayer fluidity gradient (Oberley, 1988), which could 
hamper the activities of membrane-bound enzymes and receptors. The products of 
lipid peroxidation, such as lipid radicals and lipid peroxides, are extremely harmful 
to most of the cells in the body and are associated with a variety of diseases, such 
as atherosclerosis and brain damage (Elangovan et al., 2000). It has been suggested 
that oxidative stress plays an important role in the development of chronic 
complications of diabetes (Tatsuki et al., 1997).  In our present study, there was no 
significant change in the level of TBARS in the liver of AF-, BuF- and metformin-
treated diabetic rats when compared to the vehicle-treated rats. The assessment of 
lipid peroxidation by conjugate diene levels showed a significant increase in all 
diabetic tissues except the liver. This suggests a unique response of the liver in 
STZ-induced diabetic rats to oxidative stress and supports the observation of 
Oberley (1988) that it has higher capacity to cope with the stress compared to other 
organs. Tatsuki et al. (1997) also reported that there was no change in the liver 
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lipid peroxides of STZ-diabetic rats after 2-weeks of STZ-administration at an i.v. 
dose of 32-mg/kg per day. Hence the lack of change in the TBARS levels in the 
liver of AF-and BuF-treated and metformin-treated diabetic rats could again reflect 
the resistance of the liver to the oxidative stress in the diabetic state.  It is 
significant to note that neither AF nor BuF affects this capacity adversely. AF has 
the ability to reduce the formation of TBARS like ABe; it could also potentially 




Experiment 3: Studies on the pancreatic β-cell protective effects of ABe, AF 
and BuF against STZ in SD rats 
3.1 Aims 
To evaluate the pancreatic β-cell protective action of ABe, AF, and BuF against 
STZ in SD rats. 
 
3.2 Experimental procedure 
            3.2.1 Pancreatic β-cell protective study with ABe 
Twenty-eight SD rats were randomly divided into four groups of seven rats each.  
On day zero, the body weights were recorded. The two treatment groups were 
given ABe at a dose of 125 mg/kg twice a day for 7 and 14 days respectively, 
whereas the other two groups were untreated and served as controls.  On day 8 or 
15, the body weights were recorded in the respective treatment and control groups 
and   blood samples were taken from the tail vein for glucose estimation, followed 
by STZ injection (i.p. 60 mg/kg). On day 11 or 18, the rats were fasted till the next 
morning, and decapitated to collect blood for the estimation of glucose. The liver, 
pancreas, kidneys and heart were removed and weighed. 
 
3.2.2 Studies on the pancreatic β-cell protective effect of AF and BuF 
Twenty-eight SD rats were randomly divided into four groups of seven rats each.  
The treatment groups were given AF or BuF at a dose of 125 mg/kg twice a day 
for 14 days; the other two groups were untreated. On day 15, after overnight 

























































Day 3   *
Figure 14. Effects of STZ on body weights in control and 1-week ABe-
treated SD rats. Columns represent the mean ± SEM (n=7). 
 
*P< 0.05 compared with control (Student’s t-test). 
Figure 15. Effects of STZ on body weights in control and 2-week ABe-
treated SD rats. Columns represent the mean ± SEM (n=7). 
 
*P< 0.05 compared with control (Student’s t-test). 
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group were injected intraperitoneally with a single dose of 60 mg/kg STZ. Another 
untreated group served as normal control. Fasting blood samples were collected on 
day -14 (before giving the AF and BuF), day 0 (before injecting the STZ) and on 
day 3 after injecting STZ, for the determination of serum glucose and insulin 
levels. 14 days after injecting STZ, all rats were fasted overnight and killed by 
decapitation. Blood samples were collected for determination of glucose and 
insulin levels. Pancreases were weighed and immediately frozen in liquid nitrogen 
and stored at –70°C for assays. 
 
 3.3 Results and discussion 
The body weights of the control groups, on day 3 after STZ injection, were 
significantly lower than day 0 values (P<0.05), whereas there was no significant 


























































































Figure 16. Effects of STZ on FBG levels in control and 1-week ABe-treated 
SD rats. Columns represent the mean ± SEM (n=7). 
 
*P < 0.05 compared with control (Student’s t-test). 
Figure 17. Effects of STZ on FBG levels in control and 2-week ABe-treated 
SD rats. Columns represent the mean ± SEM (n=7). 
 
*P < 0.05 compared with control (Student’s t-test). 
 77
As shown in Figure 16 & 17, the fasting serum glucose levels were significantly 
increased in both control as well as ABe-pre-treated groups on day 3 after STZ 









































































































     *
Figure 18. Effects of STZ on weights of vital organs in control and 1-week ABe-
treated SD rats. Columns represent the mean ± SEM (n=7). 
 
*P < 0.05 compared with control (Student’s t-test).
Figure 19. Effects of STZ on weights of vital organs in control and 2-week ABe-
treated SD rats. Columns represent the mean ± SEM (n=7). 
 
* P < 0.05 compared with control (Student’s t-test). 
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The weights of the pancreases of both 1 and 2 week ABe pre-treated rats were 


























































































C o n t r o l
T e s t
*
Figure 20. Effects of STZ on fasting serum insulin levels in control and 1-week ABe-
treated SD rats. Columns represent the mean ± SEM (n=7). 
Figure 21. Effects of STZ on fasting serum insulin levels in control and 2-week ABe-




The serum insulin content on day 3 after STZ injection was significantly higher (P 
< 0.05) in 2-week ABe-pre-treated group when compared to the control group. 
However there was about 20% increase in the serum insulin in the 1 week ABe 
pre-treated group even though no statistical significance was found (Figure 20 & 
21). This indicates that ABe could protect the pancreatic β-cell destruction against 























































































































Figure 22. Effects of STZ on liver glycogen content in control and 1-week ABe-
treated SD rats. Columns represent the mean ± SEM (n=7). 
  
*P<0.05 compared with control (Student’s t-test). 
Figure 23. Effects of STZ on liver glycogen content in control and 2-week ABe-
treated SD rats. Columns represent the mean ± SEM (n=7). 
 





The hepatic glycogen content (Figure 22 & 23) was significantly higher (P < 0.05) than 






















The fasting serum glucose levels were significantly increased in diabetic control group 
on  7 and 14 days after STZ injection (both P < 0.001), and also in the STZ-injected AF 
and BuF pre-treated groups as compared to normal control group (both P < 0.05) 
[Figure 24]. 
 
Figure 24.  Effects of 14-day pre-treatment with AF and BuF at a dose of 125 
mg/kg on fasting blood glucose levels on STZ-induced diabetic rats. Columns 
represent the mean ± SEM (n=7). 
 
*P < 0.05 compared to the normal control (Student’s t-test). 










































































Figure 25. Effects of 14-day pre-treatment with AF and BuF at a dose of 125 
mg/kg on serum insulin content in STZ-induced diabetic rats. Columns represent 
the mean ± SEM (n=7). 
 
* P< 0.05 compared to the normal control (Student’s t-test). 














The levels in the STZ-injected AF pre- treated group were much lower (P<0.05) 
than in the STZ-injected control group. As shown in Figure 25, the serum insulin 
level was decreased markedly in the STZ-injected control group on day 7 after 
STZ injection (P < 0.001), and this level was further decreased on day 14 (P < 
0.001). However, there was a fall in serum insulin in all the three groups on day 7 
and 14 compared to day 0. Hence, there was no difference in terms of percentage 
change between diabetic control, AF and BuF-pre-treated group. These results 
indicate that there is no much change in serum insulin observed in the AF and BuF 














































Figure 26. Effects of 14-day pre-treatment with AF and BuF at a dose of 125 
mg/kg on pancreatic insulin content in STZ-induced diabetic rats. Columns 
represent the mean ± SEM (n=7). 
 














Pancreatic insulin content was decreased by 33.6% in control animals on day 7 
after STZ injection (Figure 26). The levels in the STZ-injected AF and BuF pre-
treated rats were decreased by 21.6% and 28.5% respectively compared to the 
normal control rats, but were markedly higher compared to levels in the STZ-
injected control rats (P < 0.05).  
 
 As shown in Figure 27, pancreatic TBARS values were higher in the STZ-injected 
control, AF and BuF-treated groups than in the normal group on day 14 after STZ 
injection (P < 0.05). However there was about 7% reduction in TBARS in both AF 
and BuF-treated groups when compared to diabetic control group. 
 
 
Figure 27. Effects of 14-day pre-treatment with AF and BuF at a dose of 125 
mg/kg on pancreatic TBARS in STZ-induced diabetic rats. Columns represent 
the mean ± SEM (n=7). 
 






































The diabetogenic action of STZ in a single high dose (60 mg/kg) injection destroys 
most of the β-islet cells of pancreas. Thus high dose STZ-induced diabetes is an 
animal model of IDDM. The 2 weeks pre-treatment with ABe caused a significant 
attenuation of the severity of high dose STZ-induced diabetes when compared to 
the 1 week pre-treatment. Similarly, pretreatment with the semi-purified fraction 
for 2 weeks AF could attenuate the severity of high dose STZ-induced diabetes. 
Both acute and chronic elevations in glucose concentration stimulate the rate of 
insulin biosynthesis. Acute stimulation results in increased insulin at the 
translational level (Itoh and Okamoto, 1980), whereas chronic stimulation 
enhances the formation and/or stability of insulin mRNA (Giddings, 1985). So a 
steady-state insulin mRNA level is important for regulation of insulin production 
(Permutt, 1984). Two non-allelic insulin genes (insulin I and insulin II) have been 
identified in rats (Clark, 1969; Lomedico, 1979). The variation was taken as 
evidence for an independent regulation of the two genes, whereby the insulin I 
gene is preferentially expressed under stimulatory conditions (Kakita, 1982). Ling 
et al., (1998) noted that an elevated ratio of insulin I over insulin II in pancreatic 
tissue is a marker for a prolonged exposure to elevated glucose levels, since there 
is a transcriptional and/or a posttranscriptional failure in elevating insulin II 
formation while insulin I production is stimulated in the glucose-activated β-cells. 
The β-cells in the diabetic control group could not synthesize enough insulin 
products under stimulated conditions. This was confirmed by the finding that the 
pancreatic insulin content was significantly lower in the diabetic control group as 
compared to the normal group. However the pancreatic insulin level was 
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significantly higher than the diabetic control group in the AF-pretreated group. 
Moreover, AF-pretreatment causes better preservation of pancreatic insulin content 
than BuF. These findings showed that the pre-treatment of ABe and AF at a dose 
of 125 mg/kg can protect β-cells against STZ.        
 
A glucose molecule with a highly reactive nitrosourea side-chain in STZ is 
considered to initiate its cytotoxic action as this glucose moiety binds to a 
membrane receptor, which most likely is a glucose transporter, to cause structural 
damage (Rodrigues, 1999). Some works have previously reported that various 
carbohydrate compounds, such as 5-thio-D-glucose (Wang et al, 1993), 3-O-
methyl-D-glucose (Ganda et al., 1976), 2-deoxy-D-glucose (Dulin and Wyse, 
1969) and 4, 6-O-ethylidene glucose (Kawada et al., 1987), protected against the 
diabetogenic effect of a single high dose of STZ.   
 
The methyl-nitrosourea moiety of STZ can cause DNA breaks by alkylating DNA 
bases at various positions and lead to profound NAD depletion linked to 
stimulation of the activity of the nuclear enzyme, poly (ADP-ribose) synthetase, 
for the excision and repair of the broken DNA strands (Yamamoto et al., 1981). 
These are responsible for the deterioration in insulin synthesis and secretion 
(Okamoto et al., 1996). Therefore, poly (ADP-ribose) synthetase inhibitors such as 
nicotinamide and 3-aminobenzamide could prevent the onset of diabetes (Uchigata 
et al., 1983).  Whether ABe and AF can inhibit poly (ADP-ribose) synthetase 
activity to protect β-cells from NAD+ depletion is not clear .and further 
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experiments are necessary to confirm it.  It has been proposed that oxygen free 
radicals are involved secondarily in the mechanism of action of STZ (Baynes, 
1991). Gandy et al (1982) found that hydrogen peroxide was produced in 
pancreatic islets upon STZ exposure in vivo. 
 
Some free radical scavengers, such as nickel chloride (NiCl2) (Novelli, 1988) and 
metallothionein (Yang and Cherian, 1994), have been demonstrated to provide 
some protection against the diabetogenic properties of STZ. In this study, the 
finding of a markedly increased pancreatic lipid peroxidation level in the diabetic 
control group is in agreement with the previous report of Yang and Cherian 
(1994). The percentage of reduction in TBARS in the AF and BuF-pre-treated 
groups were about 7%. However the pancreatic insulin content in the AF and BuF-
pre-treated groups were 18% and 10% respectively. Based on the increase in 
pancreatic insulin content in the AF-pre-treated group as well as partial reduction 
in the TBARS when compared to diabetic control group, we can conclude that AF-











Experiment 4: Evaluation of the anti-diabetic effects of AF and BuF in a rat 
model of type 2 diabetes 
 4.1 Aims 
In the present study, the antidiabetic effects of AF (125 mg/kg) and BuF (125 
mg/kg) were evaluated in a rat model of type 2 diabetes. 
            
            4.2 Experimental procedure 
4.2.1 Induction of type 2 diabetes mellitus in SD Rats  
Diabetes was induced according to Method 2.3 (refer to page 31)  
 
4.2.2 The OGTT in HFD-STZ - diabetic SD rats treated with semi-purified 
fractions of ABe 
Prior to OGTT, HFD-STZ-diabetic rats were fasted for 16 h. Distilled water 
(Control), Four different fractions of ABe viz., AF, BuF, EF, and HF each at a 
dose of 125 mg/kg…….(as done previously in Experiment 2.2.1, page 58). 
 
4.2.3 Twice daily administration of AF and BuF in HFD-STZ-diabetic SD rats 
The HFD fed-STZ-diabetic rats (blood glucose >350 mg/dl) were divided on day 
zero into four groups (each with 9 rats).  The fasting blood glucose level was 
measured on day zero at 9.00 am.  Distilled water, AF (125 mg/kg), BuF (125 
mg/kg) and metformin (500 mg/kg) were then administered orally twice a day at 
9.00 am and 9.00 pm to diabetic control, treatment and positive control groups 
respectively for 2 weeks.  Body weight, food and water intakes were monitored 
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every day between 9.00 and 10.00 am for 2 weeks.  On the morning of the 15th day, 
after overnight fasting, the rats were decapitated and the blood was collected for 
estimation of the FBG, TC, TG, and HDL-C.  The organs such as liver and kidney 
were isolated, weighed and stored at -70°C for the assay of hepatic Glc-6-Pase, 











































Figure 28.  Effects of the semi-purified fractions of ABe on OGTT in HFD-STZ-diabetic rats. The 
graph represents the mean percentage changes in blood glucose concentration over – 30 min level. 
The bars represent SEM (n = 6). The oral glucose tolerance test (OGTT) in HFD-STZ-diabetic rats 
using the semi-purified fractions of A.bilimbi leaf (ABe).  The graph represents the mean 
percentage changes in blood glucose concentration over – 30 min level in vehicle (465 ± 25), 
Aqueous Fraction [AF] (446± 34), Butanol Fraction [BuF] (510 ± 42), Ethyl acetate Fraction [EF] 
(467 ± 24), and Hexane Fraction [HF] (526 ± 21) of ABe, each at a dose of 125 mg/kg and 
metformin (522 ± 37)–treated (500 mg/kg) diabetic rats, while bars represent SEM (n = 5-6).  The 
blood glucose concentration (mg/dL) of each group at –30 min is given in brackets  
*P<0.05 BuF-treated group vs vehicle-treated group (Student’s t-test). 
**P<0.01 Metformin-treated group vs vehicle-treated group (Student’s t-test). 
 #P<0.05 AF-treated group vs vehicle-treated group (Student’s t-test). 






























































            4.3 Results and discussion 
The HFD-STZ-induced diabetic rat is one of the animal models of human NIDDM 
or type 2 diabetes mellitus (Reed et al., 1999).  The present study revealed that AF 
and BuF have potent hypoglycemic and hypotriglyceridemic properties when 
given for 2 weeks to HFD-STZ-diabetic rats.  In the OGTT (Figure 28), AF (125 
mg/kg) caused a significant hypoglycemic effect at 30 min, 60 min, 120-min and 
180 min when compared with vehicle control. BuF (125 mg/kg) had no significant 
effect on blood glucose except at 60 min after oral administration (P<0.05). The 
other two-fractions, EF and HF did not cause any reduction in blood glucose level 




































Table 7. Body weight, water and food intakes in HFD-STZ-diabetic rats before and 
after oral treatment with vehicle, AF, BuF, and metformin twice a day for 2 weeks  
 
 
 ¶The percentage change from day 0 is indicated in the brackets. 










     Body weight (g) 
       (mean ± SEM) 
   Water (mL/rat/day) 
     ( mean ± SEM) 
    Food (g/rat/day) 
     ( mean ± SEM) 
 
   Treatment group 
          (n = 9) 













224 ± 5  
225 ± 6 
231 ± 11 
226 ± 9 
239 ± 11 (7) 
246 ± 19 (9) 
253 ± 25 (9) 
247 ± 14 (9)
176 ± 21 
148  ± 29 
155 ± 12 
163 ± 14 
186 ± 16 (6) 
157 ± 24 (6) 
178 ± 15 (14)
167 ± 16 (2)
42 ± 4 
35 ± 5 
45 ± 3 
42 ± 2 
60 ± 5 (43) 
43 ± 4 (23) 
46 ± 4 (2) 
43 ± 3* (2) 
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The body weight, food and water intakes of the rats did not differ significantly in 
AF- and BuF-treated diabetic rats (Table 7). However the change in mean body 
weight, food and water intakes in AF-treated group were 9%, 23% and 6% and in  
BuF-treated group were 9%, 2% and 15% respectively when compared to the day 
0 values. On the other hand, the change in mean body weight, food and water 
intakes in diabetic control group were 6%, 5% and 43% when compared to the day 
0 values. The water intake in the AF and BuF-treated groups were much lower 
when compared to the diabetic control group. However the water intake in the 
BuF-treated group was much higher than the AF-treated group. The control of 
blood glucose level in the AF-treated group could have been the reason for the 









































  *   *
    *
        **
     
**
Figure 29. Effects of the semi-purified fractions of ABe, AF and BuF, on FBG 
levels in HFD-STZ-diabetic rats.  
The FBG levels were measured on day 0, day 7, and day 14 at 9.00 a.m. after a 
16-hour fast in the vehicle (distilled water), AF (125 mg/kg), BuF (125 mg/kg) 
and metformin (500 mg/kg)-treated HFD-fed STZ-diabetic rats. Columns 
represent the mean ± SEM (n = 9). 
 
*P<0.05 compared with the diabetic untreated rats (Student’s t-test). 







AF caused a significant (P<0.01) time-dependent hypoglycemic effect (Figure 29) 
after twice-daily oral administration of 125 mg/kg BW for 7 and 14 days. BuF also 
showed a significant (P<0.05) hypoglycemic property on day 7 as well as on day 






















Both AF and BuF administration significantly (P<0.01) reduced the serum triglycerides 
(Figure 30) on day 7 and 14. The reduction in the serum TG after  daily administration of AF 
(125 mg/kg) and BuF (125 mg/kg) to HFD-STZ-diabetic rats twice a day for two weeks could 
be due to the reduction of  serum non-esterified fatty acids (NEFA) in the HFD-STZ-diabetic 
rats similar to masoprocol (nordihydroguaiaretic acid), a pure compound isolated from Larrea 






























Figure 30. Effects of the semi-purified fractions of ABe, AF and BuF, on the serum TG 
levels in HFD-STZ- diabetic rats. 
The serum TG levels were measured on day 0, day 7, and day 14 at 9.00 a.m. after a 16-
hour fast in the vehicle (distilled water), AF (125 mg/kg), BuF (125 mg/kg) and metformin 
(500 mg/kg)-treated HFD-fed STZ-diabetic rats.Columns represent the mean ±SEM(n =9).  
 
*P<0.01 compared with control rats (Student’s t-test). 




















Figure 32. Effects of the semi-purified fractions of ABe, AF and BuF, on the 
serum HDL-C levels in HFD-STZ- diabetic rats. 
The serum HDL-C levels were measured on day 0, day 7, and day 14 at 9.00 
a.m. after a 16-hour fast in the vehicle (distilled water), AF (125 mg/kg), BuF 
(125 mg/kg) and metformin (500 mg/kg)-treated HFD-fed STZ-diabetic rats. 

































Figure 31. Effects of the semi-purified fractions of ABe, AF and BuF, on serum 
TC levels in HFD-STZ- diabetic rats. 
The serum TC levels were measured on day 0, day 7, and day 14 at 9.00 a.m. after 
a 16-hour fast in the vehicle (distilled water), AF (125 mg/kg), BuF (125 mg/kg) 
and Metformin (500 mg/kg)-treated HFD-fed STZ-diabetic rats. Columns 































However there was no significant change in serum TC (Figure 31) and HDL-C 











































Figure 33. Effects of the semi-purified fractions of ABe, AF and BuF on the serum 
insulin levels in HFD-STZ- diabetic rats. 
The serum insulin levels were measured on day 0, day 7, and day 14 at 9.00 a.m. 
after a 16-hour fast in the vehicle (distilled water), AF (125 mg/kg), BuF (125 
mg/kg) and metformin (500 mg/kg)-treated HFD-fed STZ-diabetic rats. Columns 



























Figure 34. Effects of the semi-purified fractions of ABe, AF and BuF on the serum 
leptin levels in HFD-STZ- diabetic rats. 
The serum leptin levels were measured on day 0, day 7, and day 14 at 9.00 a.m. 
after a 16-hour fast in the vehicle (distilled water), AF (125 mg/kg), BuF (125 
mg/kg) and metformin (500 mg/kg)-treated HFD-fed STZ-diabetic rats. Columns 











   
   












Moreover, the serum insulin (Figure 33) and leptin levels (Figure 34) were not 







































































































Figure 35. Effects of the semi-purified fractions of ABe, AF and BuF, on the Glc-
6-Pase activity in HFD-STZ- diabetic rats. 
The Glc-6-Pase activity in the vehicle (distilled water), AF (125 mg/kg), BuF (125 
mg/kg) and metformin (500 mg/kg)-treated HFD-fed STZ-diabetic rats. Columns 
represent the mean ± SEM (n = 9). 
            










In this study, Glc-6-Pase activity (Figure 35) in the liver was significantly reduced 
(P<0.05) in both AF- and metformin-treated groups when compared to the vehicle-
treated diabetic control group. However, there was no significant change in the 
Glc-6-Pase activity of BuF –treated group.  Excessive production of glucose is the 
major cause of fasting hyperglycemia in human (Bell et al., 1986; Defronzo, 1988) 
and experimental diabetes mellitus (Chen et al., 1975; Rossetti et al., 1993). The 
hydrolysis of hepatic Glc-6-Pase is the “final common pathway” for the release of 
glucose into the circulation.   Recent experimental evidence supports the notion 
that this final step is rate-determining for the increased rate of hepatic glucose 
output in diabetic states.  
 
In fact, marked changes in the rate of formation of hepatic Glc-6-P through 
gluconeogenesis fail to alter hepatic glucose production (Puhakainen et al., 1991), 
and in experimental diabetes hepatic glucose production is markedly elevated in 
the presence of a significant decrease in the hepatic Glc-6-P pool (Rossetti et al., 
1993; Barzilai and Rossetti, 1993). Haber et al. (1995) have recently reported a 
marked increase in hepatic Glc-6-Pase mRNA and protein in diabetic BB rats. In 
the same study, in vivo treatment with 0.5 unit of insulin normalized the plasma 
glucose concentration and the hepatic Glc-6-Pase mRNA levels in diabetic rats 
within 4 h. Similarly, Liu et al. (15) have shown increased hepatic Glc-6-Pase 
mRNA and activity in STZ-induced diabetic rats.   Massillon et al. (1996) 
confirmed that prolonged insulin deficiency and hyperglycemia (experimental 
diabetes) cause a marked increase in the hepatic Glc-6-Pase mRNA and protein 
and indicate that short-term (8 h) correction of hyperglycemia in diabetic rats leads  
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to normalization of the hepatic gene expression of this enzyme, regardless of the 
circulating insulin concentrations. These studies confirmed that in vivo gene 
expression of Glc-6-Pase in the diabetic liver is regulated by glucose independent 
of insulin. 
 
It has been documented that consumption of high fat or high simple sugar diets can 
lead to insulin resistance in rats (Grundlege and Thenen, 1982; Storlien et al., 
1991; Storlien et al., 1993). Kragen et al. (1991) reported that high fat feeding 
induced insulin resistance initially in rat liver and adipose tissues, followed by 
impaired glucose metabolism in skeletal tissues. The rats fed high simple 
carbohydrate or high fat diets had significantly higher fasting plasma insulin and 
glucose levels compared to control animals, characteristic symptoms of insulin 
resistance. The nutritional state is a factor known to affect hepatic glycogen levels 
and the glycogenolytic state, as seen in livers from fasted, fed and fasted-refed rats 
(Nur et al., 1995; Tosh et al., 1994). In comparison to control animals, hepatocytes 
from rats fed high simple sugar or high fat diets had significantly decreased 
activated glycogen synthase activity. This was true for both basal GS activity and 
activity stimulated by insulin. A significant inhibition of glucose incorporation into 
glycogen was observed in rats fed a high fat diet (Oakes et al., 1997). These results 
support the findings that high fat and high simple sugar diets lead to insulin 
resistance as observed in lower rates of both GS activity and expression than in 
control animals. Hepatic insulin resistance is a major defect of non-insulin 



































Figure 36. Effects of the semi-purified fractions of ABe, AF and BuF, on hepatic 
glycogen content in HFD-STZ- diabetic rats. 
The hepatic glycogen content in the vehicle (distilled water), AF (125 mg/kg), BuF 
(125 mg/kg) and metformin (500 mg/kg)-treated HFD-fed STZ-diabetic rats. 
Columns represent the mean ± SEM (n = 9). 
            











deposition from glucose is impaired in diabetic animals (Ciudad et al., 1988; 
Bollen et al., 1998). 
 
Glycogen deposition was also impaired in diabetic rats where the activation of 
glycogen synthase is either impaired or absent, in proportion to the severity of 
insulin deficiency (Langdon and Curnow, 1980). In this study, the liver glycogen 
content was markedly lower in diabetic control rats whereas the glycogen content 
was significantly higher in AF-treated rats (Figure 36) 
 
Insulin regulates blood glucose homeostasis by stimulating the utilization of 
glucose by the liver, muscle and adipose tissue. In the liver, insulin stimulates 
glycogen synthesis, glycolysis and fatty acid synthesis, but unlike muscle and 
adipose tissue, it does not stimulate glucose transport. The conversion of glucose 
to glycogen in liver cells is dependent on the extracellular glucose concentration 
and on the presence of insulin, which stimulates glycogen synthesis over a wide 
range of glucose concentrations (Stalmans et al., 1997). Hepatic glycogen 
synthase, the rate-limiting enzyme of the glycogen synthetic pathway, is controlled 
by intricate mechanisms involving multisite phosphorylation as well as allosteric 
regulation (Wititsuwannakul and Kim, 1979; Nuttall et al., 1988). Its activity is 
increased in liver from diabetic rats (Bahnak and Gold, 1982; Niewoehner et al., 
1986). This increase in activity could be due to an increased mass of the enzyme or 
to the presence of a more catalytically efficient form(s) of the enzyme. Although 
total activity may be enhanced in diabetic animals, the percent of activated GSI 
was significantly lower compared to hepatocytes from healthy control animals 
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(Gannon and Nuttall., 1997).  Conflicting data has been reported by other 
investigators. Rao et al. (1995) reported no change in total glycogen synthase 
activity in livers of diabetic rats, but a significantly lower GSI activity. Recently, 
Wang et al. (1998) reported that both total GS and GSI activity were significantly 
lower in livers of STZ-diabetic rats. In primary hepatocyte culture isolated from 
normal and diabetic adult rats, it was shown that both glucose and insulin activate 
glycogen synthesis in primary culture hepatocytes from normal but not diabetic 
rats (Miller et al., 1986). Van Auken et al. (1996) reported that total GS activity in 
the diabetic cells at physiologic glucose concentrations was significantly higher 
than that for normal cells; however, the amount of active synthase was twofold 
lower than that of normal cells. Additionally, in normal hepatocytes, chronic (48 h) 
exposure to increasing concentrations of glucose was found to up-regulate total 
synthase activity, synthase protein and synthase mRNA levels. All three of these 


























Table 8.  Liver cytochrome P450 content and TBARS levels in the kidney and 
liver of HFD-STZ-diabetic rats after twice-a-day oral treatment for 2 weeks 
with vehicle, AF, BuF, and metformin  
 














(nmol of malonaldehyde per 
25 mg of tissue) 
 
 
Treatment group  




(mean ± SEM) 
 
Hepatic cytochrome P450 
content 
(nmol/mg protein) 












            
 
4.5 ± 0.4 
4.3± 0.3 
4.2 ± 0.3 
4.6 ± 0.2 
4.8± 0.3 
4.5± 0.6 
4.3 ± 0.3 
4.2  ± 0.3 
1.34 ± 0.02 
1.28 ± 0.06 
1.35 ± 0.09 
1.22 ± 0.07* 
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The kidney TBARS in metformin-treated diabetic rats were significantly lower 
than (P < 0.05) in the vehicle-treated rats (Table 8).   On the other hand, the kidney 
TBARS value in AF and BuF-treated rats were not significantly different from that 
in the vehicle-treated rats. However the percentage of reduction in kidney TBARS 
was about 6% and 11% in AF and BuF-treated groups respectively when compared 
to the vehicle-treated control group. Similarly, there was no difference in liver 
TBARS values between AF, BuF and metformin-treated rats and vehicle-treated 
control rats. However the percentage of reduction in liver TBARS was about 6% 
and 7% in AF and BuF-treated groups when compared to the vehicle-treated rats. 
However there was about 2% increase in TBARS in metformin-treated group when 
compared to vehicle-treated rats. Based on the observation, the BuF reduced the 
TBARS better than AF.  The liver microsomal cytochrome P450 content was 
significantly lower in the metformin-treated rats when compared to that in the 
corresponding vehicle-treated rats. However, there was no significant difference in 
the liver cytochrome P450 content in AF- and BuF-treated rats when compared 
with that in the corresponding vehicle-treated rats. Similar effects on kidney and 
liver TBARS and liver microsomal P450 content were produced by AF and BuF in 







          Experiment 5: Identification of bioactive principle (s) in ABe, AF and BuF 
           5.1 Aims 
In this study, ABe, AF and BuF were analyzed by RP-HPLC and AAS for the 
presence of anti-diabetic principle (s). Its effects on glucose tolerance in animals 
with experimental diabetes mellitus were evaluated. 
 
5.2 Experimental procedure 
5.2.1 RP-HPLC of ABe, AF and BuF  
The RP-HPLC was done according to the procedure described in Method 2.20 
(page 40). 
             
            5.2.2. AAS analysis of ABe, AF and BuF 
The AAS analysis of ABe, AF, and BuF was done according to the procedure 
















    








Figure 38. RP-HPLC finger print of ABe. 
 


















           5.3. Results and discussion 
 
Nicotinic acid (NA) and nicotinamide (NAM) are commonly called niacin (Figure 
37).  NA is the predominant form of niacin found in plant products.  In our studies, 
the RP-HPLC analysis of the 80% ethanolic leaf extract of A. bilimbi (ABe), as 
well as AF and BuF showed the presence of nicotinic acid or niacin (Figure 38, 39 
& 40) at the amount of 174.4 ± 1.8, 73.9 ± 2.7, and 55.8 ± 2.1mg/g respectively 
(Table 9).  NA and NAM are the dietary precursors for NAD (nicotinamide 
adenine dinucleotide), which is required for DNA synthesis, as well as for the 
activity of the enzyme poly (ADP-ribose) polymerase-1 (PARP-1) for which NAD 
is the sole substrate. The enzyme PARP-1 is highly activated by DNA strand 
breaks during the cellular genotoxic stress response, is involved in base excision 
repair, plays a role in p53 expression and activation, and hence, is thought to be 
important for genomic stability. In vitro as well as animal studies indicate that 
niacin deficiency increases genomic instability especially in combination with 
genotoxic and oxidative stress. NA and NAM are rapidly absorbed from the 
stomach and the intestine. Within normal dietary intakes, most of the dietary NA is 
converted to NAD in the intestine or liver, and is cleaved by NAD glycohydrolase 
to release NAM into the portal or systemic circulation. NAM is the major form in 
the bloodstream and is obtained from NAD and NADP in animal products in the 
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ABe 174.4 ± 1.8 12.8 <0.1 1.9 7 
AF 73.9 ± 2.7 11.0 Undetected 1.0 5.6 
BuF 55.8 ± 2.1 1.6 Undetected <0.1 <0.1 
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AAS analysis showed the presence of magnesium (Mg) and other metals such as 
vanadium and manganese. Mg level was low in BuF (Table 9). Intracelluar 
deficiency of some trace elements has been shown in diabetes, obesity, and 
hypertension (Failla and Kiser, 1981; Paolisso et al., 1987; Paolisso et al., 1988; 
Raz., et al., 1988). Over the last several years, numerous reports have confirmed the 
in vitro and in vivo insulin-like activity of several elements. Vanadate and lithium 
have been shown to stimulate glucose uptake and glycogen synthase activity in 
heptatocytes, adipocytes, diaphragm, and skeletal muscle (Bosch et al., 1986; 
Bhattacharya, 1964; Dubyak and Kleinzellar, 1980; Green, 1986; Duckworth et al., 
1988).  Recently, Ho et al., (2000) reported that high zinc intake significantly 
reduced the severity of type 1 diabetes in alloxan and STZ animal models. 
 
Since NA and Mg were identified in ABe and its bio-active fractions, their effects 











Experiment 6: Evaluation of the synergistic interaction of magnesium and 
nicotinic acid on glucose tolerance in animals with experimental diabetes 
mellitus 
            
          6.1 Aims 
In this study the synergistic interaction of Mg and NA on glucose tolerance was 
tested in animals with both type 1 and type 2 diabetes mellitus. 
           
             6.2 Experimental procedure 
 6.2.1 The OGTT in STZ - diabetic SD rats using MgCl2 
Prior to OGTT rats were fasted for 16 h.  Distilled water (normal and diabetic 
control), a reference drug metformin (500 mg/kg), or each of four different doses 
of MgCl2 (10 mg, 50 mg, 100 and 600 mg/kg) was then orally administered to 
groups of 6 rats each….. (as done previously in Experiment 2.2.1, page 58). 
 
6.2.2 The OGTT in STZ - diabetic SD rats using NA 
Prior to OGTT rats were fasted for 16 h.  Distilled water (control), a reference drug 
metformin (500 mg/kg), or each of four different doses of nicotinic acid (10 mg, 
50 mg, 100 and 2 g/kg) was then orally administered to groups of 6 rats 
each…..(as done previously in Experiment  2.2.1, page 58). 
 
6.2.3 The OGTT in STZ - diabetic SD rats using MgCl2 and NA 
Prior to OGTT rats were fasted for 16 h.  Distilled water (normal and diabetic 
control), a reference drug metformin (500 mg/kg), or each of four different doses 
of MgCl2 and NA (MgCl2 10 mg + NA 10 mg/kg, MgCl2 50 mg + NA 50 mg/kg, 
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MgCl2 100 mg + NA 100 mg/kg, and MgCl2 600 mg + NA 2 g /kg) was then 
orally administered to groups of 6 rats each….(as done previously in Experiment  
2.2.1, page 58). 
 
6.2.4 The OGTT in HFD-STZ - diabetic SD rats using MgCl2 
The OGTTs were performed in HFD-STZ-diabetic rats using MgCl2 by the same 
procedure as described for the STZ-diabetic rats (refer to Experiment 6.2.1). 
             
6.2.5 The OGTT in HFD-STZ - diabetic SD rats using NA 
The OGTTs were performed in HFD-STZ-diabetic rats using NA by the same 
procedure as described for the STZ-diabetic rats (refer to Experiment 6.2.2). 
 
6.2.6 The OGTT in HFD-STZ - diabetic SD rats using MgCl2 and NA 
The OGTTs were performed in HFD-STZ-diabetic rats using MgCl2 and NA by 
the same procedure as described for the STZ-diabetic rats (refer to Experiment 
6.2.3). 
 
           6.2.7 The IPGTT in STZ – C57BL/6J mice using MgCl2 
 
Before the IPGTT, animals were fasted for 4 h (Starting from 9.00 a.m.) Distilled 
water (normal and diabetic controls), a reference drug metformin (500 mg/kg), or 
each of four different doses of MgCl2 (10 mg, 50 mg, 100 mg and 600 mg/kg) was 
then orally administered to groups of 6 mice each and followed by an i.p. 
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administration of glucose (2 g/kg). Blood glucose levels were determined in tail 
blood samples at -30 (just before the MgCl2 and metformin administration), 0 (just 
before the i.p. administration of glucose), 120 and 180 min after glucose load for 
the estimation of glucose by i-STAT blood glucose analyzer.  
 
6.2.8 The IPGTT in STZ – C57BL/6J using NA 
Before the IPGTT, animals were fasted for 4 h (Starting from 9.00 a.m.) Distilled 
water (normal and diabetic controls), a reference drug metformin (500 mg/kg), or 
each of four different doses of NA (10 mg, 50 mg, 100 mg and 2 g/kg) was then 
orally administered to groups of 6 mice  each and ….(as done previously in 
Experiment 6.2.7). 
 
 6.2.9 The IPGTT in STZ – C57BL/6J using MgCl2 and NA 
Before the IPGTT, animals were fasted for 4 h (Starting from 9.00 a.m.) Distilled 
water (normal and diabetic controls), a reference drug metformin (500 mg/kg), or 
each of four different doses of MgCl2 and NA (MgCl2 10 mg + NA 10 mg/kg, 
MgCl2 50 mg + NA 50 mg/kg, MgCl2 100 mg + NA 100 mg/kg, and MgCl2 600 
mg + NA 2 g /kg) was then orally administered to groups of 6 mice each and …… 




            6.2.10 The IPGTT in HFD – C57BL/6J mice using MgCl2 
The IPGTTs were performed in HFD-C57BL/6J-mice using MgCl2 by the same 




           6.2.11 The IPGTT in HFD – C57BL/6J using NA 
The IPGTTs were performed in HFD-C57BL/6J-mice using NA by the same 
procedure as described for the STZ- C57BL/6J-mice (refer to Experiment 6.2.8). 
 
            6.2.12. The IPGTT in HFD – C57BL/6J using MgCl2 and NA 
The IPGTTs were performed in HFD-C57BL/6J-mice using MgCl2 and NA by the 
same procedure as described for the STZ- C57BL/6J-mice (refer to Experiment 
6.2.9). 
 
            Figure 41. Effects of MgCl2 on glucose tolerance in STZ-diabetic rats.  
The graph represents the mean changes in blood glucose concentration, while bars  
represent ± SEM (n = 6) in the OGTT.   
P < 0.001 Metforim-treated group vs diabetic control at 0, 30, 60, 120 and 180 min 
(Student’s t-test). 
P < 0.05 MgCl2 (600 mg/kg)-treated group vs diabetic control at 60, 120 and 180 
min (Student’s t-test).  
 
































       6.3 Results and discussion 
In the OGTT (Figure 41 & 42), administration of MgCl2 at a dose of 600 mg/kg 
per orally caused a significant attenuation (P<0.05) of blood glucose at 60, 120 and 
180 min after the glucose load was given orally at 0-h in both STZ and HFD-STZ-
diabetic rats. On the other hand, the administration of MgCl2 at doses of 10 mg, 50 
mg and 100 mg/kg did not cause any improvement in the glucose tolerance in both 
STZ as well as HFD-STZ-diabetic rats.  
 
 
Figure 42.  Effects of MgCl2 on glucose tolerance in HFD-STZ diabetic rats.  
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the OGTT.   
P < 0.001 Metforim-treated group vs diabetic control at 0, 30, 60, 120 and 180 min 
(Student’s t-test). 
 
P < 0.05 MgCl2 (600 mg/kg)-treated group vs diabetic control at 60, 120 and 180 
min (Student’s t-test). 
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Figure 43.  Effects of NA on glucose tolerance in STZ-diabetic rats.  
 
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the OGTT.   
 
P < 0.001 Metforim-treated group vs diabetic control 0, 30, 60, 120 and 180 min 
(Student’s t-test). 





































Similarly, in the OGTT (Figure 43 & 44), administration of NA at doses of 10 mg, 
50 mg and 100 mg/kg per orally did not cause attenuation of blood glucose, where 
as the administration of NA at a dose of 2 g/kg caused significant improvement 
(P<0.05) in the glucose tolerance in both STZ as well as HFD-STZ-diabetic rats at 




         Figure 44.  Effect of NA on glucose tolerance in HFD-STZ-diabetic rats.  
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the OGTT.   
P < 0.001 Metforim-treated group vs diabetic control at 0, 30, 60, 120 and 180 min 
(Student’s t-test). 
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Figure 45. Effects of MgCl2 and NA on glucose tolerance in STZ-diabetic rats.   
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the OGTT.   
P < 0.05 MgCl2 + NA (each 10 mg/kg) -treated group vs diabetic control at 120 
and 180 min (Student’s t-test). 
P < 0.05 MgCl2 + NA (each 50 mg/kg)-treated group vs diabetic control at 60, 120 
and 180 min (Student’s t-test). 
 
P < 0.05 MgCl2 + NA (each 100 mg/kg)-treated group vs diabetic control at 60, 
120 and 180 min (Student’s t-test). 
 
P < 0.01 MgCl2 (600 mg/kg) + NA (2 g/kg)-treated group vs diabetic control at 60, 
120 and 180 min (Student’s t-test). 
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However, the administration of each of four different doses of MgCl2 and NA 
(MgCl2 10 mg + NA 10 mg/kg, MgCl2 50 mg + NA 50 mg/kg, MgCl2 100 mg + 
NA 100 mg/kg, and MgCl2 600 mg + NA 2 g /kg) increases glucose tolerance 
significantly (P < 0.05 and P<0.01 respectively) in both STZ and HFD-STZ-





        Figure 46.  Effects of MgCl2 and NA on glucose tolerance in HFD-STZ-diabetic rats.  
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the OGTT.   
P < 0.05 MgCl2 + NA (each 10 mg/kg) -treated group vs diabetic control at 60, 120 
and 180 min (Student’s t-test). 
 
P < 0.05 MgCl2 + NA (each 50 mg/kg)-treated group vs diabetic control at 60, 120 
and 180 min (Student’s t-test). 
 
P < 0.05 MgCl2 + NA (each 100 mg/kg)-treated group vs diabetic control at 60, 120 
and 180 min (Student’s t-test). 
 
P < 0.01 MgCl2 (600 mg/kg) + NA (2 g/kg)-treated group vs diabetic control at 60, 
120 and 180 min (Student’s t-test). 
 
P < 0.001 Metforim-treated group vs diabetic control at 60, 120 and 180 min 
(Student’s t-test). 
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Figure 47. Effects of MgCl2 on glucose tolerance in STZ-diabetic C57BL/6J mice. 
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the IPGTT.   









On the other hand, in the IPGTT (Figure 47 & 48), the administration of MgCl2 at 
doses of 10 mg, 50 mg, 100 mg and 600 mg/kg did not cause any improvement in 
the glucose tolerance in both STZ as well as HFD-diabetic C57BL/6J mice after 






































Figure 48. Effects of MgCl2 on glucose tolerance in HFD-induced diabetic 
C57BL/6J mice.  
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the IPGTT.   
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Figure 49. Effects of NA on glucose tolerance in STZ-diabetic C57BL/6J mice. 
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the IPGTT.   









Similarly, (Figure 49), administration of NA at doses of 10 mg, 50 mg, 100 mg and 
2 g/kg per orally did not cause attenuation of blood glucose, in STZ-diabetic 
C57BL/6J mice in the IPGTT. However, administration of 2 g/kg of NA per orally 
to HFD-diabetic C57BL/6J mice (Figure 50) caused a significant attenuation 







































Figure 50. Effects of NA on glucose tolerance in HFD-induced diabetic C57BL/6J 
mice.  
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the IPGTT.   
P < 0.05 NA (2 g/kg) vs diabetic control at 180 min (Student’s t-test). 
 










































Figure 51. Effects of MgCl2 and NA on glucose tolerance in STZ-diabetic 
C57BL/6J mice.  
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the IPGTT.   
P < 0.05 MgCl2 + NA (600 mg + 2 g/kg) vs diabetic control at 120 and 180 min 
(Student’s t-test). 
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The administration of each of four different doses of MgCl2 and NA (MgCl2 10 mg 
+ NA 10 mg/kg, MgCl2 50 mg + NA 50 mg/kg, MgCl2 100 mg + NA 100 mg/kg) 
did not increase glucose tolerance in both STZ and HFD-diabetic C57BL/6J mice 
(Figure 51 & 52). However, the administration of high doses of MgCl2 and NA 
(600 mg/kg of MgCl2 and 2 g/kg of NA in combination) caused a significant 
attenuation of blood glucose at 180 min in STZ-diabetic C57BL/6J mice and at 





Figure 52. Effects of MgCl2 and NA on glucose tolerance in HFD-induced 
diabetic C57BL/6J mice.  
The graph represents the mean changes in blood glucose concentration, while bars 
represent ± SEM (n = 6) in the IPGTT.   
P < 0.05 MgCl2 + NA (600 mg + 2 g/kg) vs diabetic control at 120 and 180 min 
(Student’s t-test). 
 
P < 0.05 Metformin-treated group vs diabetic control at 120 and 180 min 
(Student’s t-test). 
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These results indicate a synergistic interaction of MgCl2 and NA in diabetic 
animals in improving the glucose tolerance in diabetic animals. Similarly, a 
decrease in fasting blood glucose level in rats following the intraperitoneal 
administration of NA was observed (Ammon et al., 1971). The measurement of 
insulin-stimulated glucose disposal and hepatic glucose production in STZ-diabetic 
rats during an infusion of nicotinic acid has shown a decrease in plama NEFA 
accompanied by an increase in peripheral glucose disposal and a fall in hepatic 
glucose production and fasting plasma glucose was lowered (Reaven et al., 1988).   
NA does exhibit hypolipidaemic properties, and effectively lowers both TC and 
TG (Boberg et al., 1971). It inhibits fatty acid mobilization from adipose tissue 
(Carlson et al., 1968), thereby lowering plasma NEFA and inhibiting the synthesis 
of VLDL-C synthesis. 
Chronic magnesium supplementation (4.5 g) to NIDDM patients produced a 
significant reduction of the lipid profile and an increase of HDL-C. These results 
suggest that oral supplementation of magnesium may be useful in the treatment of 
hyperlipidemia in patients with non-insulin-dependent diabetes mellitus (Corica et 
al., 1994). This was recently confirmed by Lal et al. (2003). Moreover, magnesium 
supplementation in male obese Zucker diabetic fatty rats prevents deterioration of 
glucose tolerance and delayed the development of diabetes (Balon et al., 1995).  
Vanadate and lithium have been shown to stimulate glucose uptake and glycogen 
synthase activity in heptatocytes, adipocytes, diaphragm, and skeletal muscle 
(Bosch et al., 1986; Bhattacharya, 1964; Dubyak and Kleinzellar, 1980; Green, 
1986; Duckworth et al., 1988). Zinc has been shown to stimulate insulin action and 
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insulin receptor tyrosine kinase (IRTK) activity (Ezaki, 1989; Coulston and 
Dandona, 1980). The oral administration of lithium (Rossetti, 1989) and vanadate 
(Rossetti and Laughlin, 1989) improves glucose tolerance and normalizes insulin-
mediated glucose uptake, primarily through the stimulation of skeletal muscle 
glycogen synthesis.  
Mg is known to have a synergistic effect with V to increase muscle glycogen 
synthesis in diabetic rats. It was reported that neither magnesium sulfate (MgSO4) 
nor sodium vanadate (NaV) had any effect on glucose utilization. However, MgV 
was superior to either V alone or Mg alone in improving insulin sensitivity and 
glycogen synthesis in diabetic rats (Matsuda et al., 1999). So the trace elements 
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           Section 1: Summary of results 
                          This research project was designed to examine the anti-diabetic properties of 
ABe in vivo.   In our initial experiment, ABe was evaluated for its antidiabetic 
activity in STZ-induced diabetic SD rats. At a dose of 125 mg/kg body weight, 
ABe increased the glucose tolerance in OGTT. Moreover, it showed potent 
hypoglycemic, hypotriglyceridemic, anti-lipid peroxidative and anti-atherogenic 
activities when administered twice a day for 2 weeks.  
 
                          In the next experiment, anti-diabetic effects of semi-purified fractions of ABe 
were evaluated in STZ-diabetic SD rats. To obtain the semi-purified fractions, ABe 
was partitioned with organic solvents such as butanol, ethyl acetate and hexane to 
obtain AF, BuF, EF and HF soluble fractions. The hypoglycemic property of each 
fraction was then assessed by OGTT at a dose of 125-mg/kg-body weight in STZ-
diabetic rats. Fractions AF and BuF produced significant blood glucose-lowering 
effect. In the long-term study, twice a day administration of AF and BuF at a dose 
of 125 mg/kg-body weight for 14 days in both STZ-diabetic rats showed a 
significant blood glucose lowering action.  Among AF and BuF, AF was more 
potent in lowering blood glucose and increased the serum insulin level and 
lowered hepatic Glc-6-Pase activity significantly in STZ-diabetic rats.  
 
                         The third experiment was designed to investigate the β-cell protective effects of 
ABe and its bio-active fractions, AF and BuF against STZ.  The pre-treatment of 
ABe at a dose of 125 mg/kg for 14 days caused a protection against STZ induction 
of diabetes in male SD rats.  The FBG levels in the AF pre- treated STZ-diabetic 
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rats were much lower than in the vehicle-treated control group. The serum insulin 
level on day 7 after STZ was decreased markedly in both control as well as AF and 
BuF pre-treated groups and this level was further decreased on day 14 after STZ 
injection, while pancreatic insulin content was markedly higher compared to levels 
in the diabetic control rats. On the other hand, the pancreatic TBARS values were 
higher in the diabetic control, AF and BuF-treated groups than in the normal 
control on day 14 after STZ injection. However the values were significantly lower 
when compared with diabetic control.  
 
                          In the fourth experiment, hypoglycemic property of semi-purified fractions of 
ABe was examined in HFD-STZ-diabetic rats. Each fraction was assessed by 
OGTT at a dose of 125-mg/kg-body weight in HFD-STZ diabetic rats. Of which, 
fractions AF and BuF produced significant blood glucose-lowering effect. In the 
long-term study, twice a day administration of AF and BuF at a dose of 125 
mg/kg-body weight for 14 days in HFD-STZ-diabetic rats showed a significant 
blood glucose lowering action.     Moreover, among the AF and BuF, AF was more 
potent in lowering blood glucose and Glc-6-Pase activity and increased the hepatic 
glycogen content in HFD-STZ-diabetic rats compared to BuF. These results 
indicated that AF is more potent than BuF in the amelioration of diabetes in both 
STZ and HFD-STZ-diabetic rats. 
  
     In our fifth experiment, the RP-HPLC analysis of ABe, AF, and BuF showed 
the presence of NA, whereas the AAS analysis showed the presence of magnesium 
in ABe, AF and BuF in higher amount than other elements such as V, Mn++, and 
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Zn++. Hence in our final experiment, the effects of both Mg and NA on glucose 
tolerance were assessed in type 1 and type 2 animal models of diabetes. When 
given, MgCl2 and NA, together in the OGTT at doses of 10 mg, 50mg, 100 mg/kg 
each and 600 mg of MgCl2 + 2 g/kg of NA, blood glucose was attenuated 
significantly in STZ as well as HFD-STZ-diabetic rats. 
 
                          In the IPGTT of STZ-induced C57BL/6J and HFD-induced C57BL/6J mice, the 
administration of MgCl2 at the doses of 10 mg, 50 mg, 100 mg, and 600 mg/kg and 
NA at the doses of 10 mg, 50 mg, 100 mg and 2 g/kg, did not influence the glucose 
tolerance in both STZ-induced C57BL/6J and HFD-induced C57BL/6J mice. On 
the other hand, the administration of MgCl2 with NA at a dose of 600 mg/kg and 2 
g/kg respectively caused a significant blood glucose attenuating effect in both 
STZ-induced C57BL/6J and HFD-induced C57BL/6J mice.  
 










Section 2: Overall discussion 
     The present work is an attempt to evaluate the anti-diabetic properties of ABe 
in experimental animal models of diabetes mellitus. This study suggested the 
following findings. 
 
     ABe possesses a definite hypoglycemic, hypotriglyceridemic, anti-atherogenic, 
and anti-lipid peroxidative properties in STZ-diabetic rats after 2 weeks of 
treatment.  The hypoglycemic activity of ABe was observed at the lowest dose 
(125 mg/kg) in normal as well as STZ-diabetic rats.  Moreover, the daily 
administration of ABe (125 mg/kg) to STZ-diabetic rats twice a day for two weeks 
caused a significant reduction in food and water intakes, and an increase in the 
body weight.  Since ABe has the ability to reduce the formation of TBARS in the 
kidneys of STZ-diabetic rats, it could prevent platelet aggregation and thrombosis 
(Sushil Jain et al., 1998).  However, the lack of change in the TBARS levels in the 
liver of AF-and BuF-treated and metformin-treated STZ/HFD-STZ diabetic rats 
could again reflect the resistance of the liver to the oxidative stress in the diabetic 
state as observed by Oberley (1988) and Tatsuki et al (1997).  It is significant to 
note that neither AF nor BuF affects this capacity adversely. Similarly, AF and 
BuF did not cause any change in the cytochrome P450 enzymes in the liver of both 
STZ and HFD-STZ-diabetic rats, since the level of increase in hepatic cytochrome 
P450 depends on the duration of diabetes (Barnett et al., 1994) and insulin levels 




     Further studies showed that semi-purified fractions of ABe such as AF and BuF 
have potent hypoglycemic property in both STZ and HFD-STZ-diabetic rats when 
administered twice a day per orally for 2 weeks at a dose of 125 mg/kg.   Although 
the body weight of the rats did not differ significantly in both STZ and HFD-STZ-
diabetic rats, food and water intakes of AF-and BuF-treated STZ-diabetic rats were 
reduced significantly when compared to the vehicle-treated diabetic rats. Similar 
effects were reported for hypoglycemic agents such as tungstate and vanadate (Gil 
et al., 1988; Barbera et al., 1994).   
                     
                          The elevation of serum insulin in AF and BuF-treated STZ-diabetic rats could 
either be due to the insulinotropic substances present in the fractions, which induce 
the intact functional β-cells to produce insulin, or the protection of the functional 
β-cells from further deterioration so that they remain active and produce insulin. 
Similarly the extracts of Medicago sativa (Gray and Flatt, 1997), Eucalyptus 
globulus (Gray and Flatt, 1998), and Sambucus nigra (Gray et al., 2000) have been 
shown to possess insulin-releasing action both in vitro and in vivo. Since insulin 
inhibits the activity of Glc-6-Pase in the liver of STZ-diabetic rats and controls 
HGP, the insulinotropic effect of AF might play a crucial role in the control of 
hyperglycemia in STZ-diabetic rats. The suppression of Glc-6-P hydrolysis could 
also be one of the reasons for the hypoglycemic effect of AF in both STZ and 
HFD-STZ-diabetic rats. Similar effects were reported for other hypoglycemic 
agents such as vanadate compounds (Mosseri et al., 2000) which have been shown 
to inhibit hepatic Glc-6-Pase activity, thereby reducing blood glucose levels in 
NOD mice. However no significant difference was found in the hepatic glycogen 
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stores of the treated groups compared to control (Schulz, 1988). However the liver 
glycogen content was significantly higher in AF-treated HFD-STZ-diabetic rats.  It 
could be due to the HFD-feeding of rats, which causes peripheral and hepatic 
insulin resistance expressed by a decrease in peripheral glucose disposal and an 
increase in hepatic glucose uptake (Kraegen et al., 1991).  
 
                          Further investigations on the β-cell protective effects of ABe and its bio-active 
fractions, AF and BuF, at a dose of 125 mg/kg for 14 days caused protection 
against STZ induction of diabetes in male SD rats.  The ability of ABe and its 
semi-purified fraction, AF, to protect β-cells suggest that ABe and AF may prevent 
β-cell DNA break by STZ.  The methyl-nitrosourea moiety of STZ can cause DNA 
breaks by alkylating DNA bases at various positions and lead to profound NAD 
depletion linked to stimulation of the activity of the nuclear enzyme, poly (ADP-
ribose) synthetase, for the excision and repair of the broken DNA strands 
(Yamamoto et al., 1981). These are responsible for the deterioration in insulin 
synthesis and secretion (Okamoto et al., 1996). Therefore, poly (ADP-ribose) 
synthetase inhibitors such as nicotinamide and 3-aminobenzamide could prevent 
the onset of diabetes (Uchigata et al., 1983).  Whether ABe and AF can inhibit 
poly (ADP-ribose) synthetase activity to protect β-cells from NAD+ depletion is 
not clear and further experiments are necessary to confirm it.  Gandy et al., (1982) 
found that hydrogen peroxide was produced in pancreatic islets upon STZ 
exposure in vivo and the oxygen free radicals are involved secondarily in the 
mechanism of action of STZ (Baynes, 1995). The markedly increased pancreatic 
lipid peroxidation level found in the diabetic control groups in our experiments is 
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in agreement with the previous report of Yang and Cherian (1994). Hence, the 
partial inhibition of lipid peroxidation in the pancreas of AF pre-treated rats could 
contribute to the reduction of cytotoxicity of STZ against the β-cells of the 
pancreas.  
 
     Since NA and Mg were identified in both ABe and AF, the influence of these 
two components were tested on glucose tolerance in both type 1 and type 2 animal 
models of diabetes.  The administration of NA and Mg together increased glucose 
tolerance significantly in both STZ and HFD-STZ-diabetic rats in lower doses as 
well as in STZ and HFD-C57BL/6J mice at high doses.  This indicates the 
synergistic interaction of NA and Mg in controlling the glucose tolerance in 
animals with experimental diabetes mellitus. Similar interaction of NA with other 
trace metal chromium was reported by Thomas and Gropper (1996). A decrease in 
FBG level in rats following the intraperitoneal administration of NA was observed 
by Ammon et al (1971). 
 
     Even though the effects of NA on the experimental animal models of diabetes 
are relatively consistent, the acute findings in humans, on the other hand, are more 
complex and subject of controversy. The glucose tolerance in diabetic patients has 
been both worsened (Gaut and Taylor-Russell, 1968) and improved (Carlson and 
Ostman, 1965) by NA.  Though species differences may partly explain the 
discrepant findings in animals and man, the considerable variation in experimental 
conditions and in particular the lack of homogeneity in the study population also 
makes different studies difficult to compare (Reaven et al., 1988). 
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     However, Mg supplementation in male obese Zucker diabetic fatty rats prevents 
deterioration of glucose tolerance and delayed the development of diabetes (Balon 
et al., 1995).  Moreover, Mg is known to have a synergistic effect with V to 
increase muscle glycogen synthesis in diabetic rats (Matsuda et al., 1999). Thus the 
Mg in ABe and AF could interact with NA as well as other hypoglycemic metal 
elements such as vanadium and manganese (Rubenstein et al., 1962; Rubenstein et 
al., 1962; Fore, 1963; Swanston-Flatt et al., 1990) and improve glucose tolerance 























             
 
 




            
            Section 1: Conclusion 
The following results have been demonstrated 
1. The ABe at a dose of 125 mg/kg body weight caused hypoglycemic, 
hypotriglyceridemic, anti-lipid peroxidative, anti-atherogenic and β-cell 
protective activities in STZ-diabetic rats.  
2.  The semi-purified fractions of ABe such as AF and BuF at a dose of 125 
mg/kg body weight caused hypoglycemic and hypotriglyceridemic properties 
in both STZ and HFD-STZ-diabetic rats.  
3. Phytochemical analysis revealed the presence of both NA and Mg in ABe and 
AF. 
4. Further studies in STZ/HFD-STZ-diabetic rats and STZ/HFD-diabetic 
C57BL6j mice showed that the administration of both NA and Mg together 
improved the glucose tolerance significantly than Mg or NA alone.  
 
The results indicate the following: 
1. ABe, AF and BuF have potent anti-diabetic activity in animals with 
experimental diabetes. 
2. AF was more potent than BuF in reducing blood glucose and lipids as well as 
β-cell protection against streptozotocin toxicity in diabetic animals. 
3. Significant amounts of NA and Mg were present in the A bilimbi leaves. 
4. NA and Mg together had a synergistic effect on glucose tolerance in animal 
models of type 1 and type 2 diabetes. 
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            Section 2: Future studies 
1. The anti-diabetic activity of ABe, AF and BuF can be tested in genetically- 
diabetic animal models such as the BB rats, C57BL/KsJ-db/db mice and obese 
non-diabetic C57BL/6j-ob/ob mice. 
2. The synergistic interaction of NA and Mg can also be further tested in 
genetically diabetic animal models. 
3. The effects of NA and Mg on glucose uptake can be investigated in vitro in cell 
lines such as 3T3 adipocytes.  
4. ABe, AF and BuF can further be analyzed using modern liquid 
chromatographic techniques (LC) coupled with mass spectrometry (LC-MS), 
nuclear magnetic resonance spectroscopy (LC-NMR), ultra-violet spectroscopy 
(LC-UV) and infrared spectroscopy (LC-IR) for the identification and isolation 
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